Page last updated: 2024-08-23

paclitaxel and Epithelial Neoplasms

paclitaxel has been researched along with Epithelial Neoplasms in 302 studies

Research

Studies (302)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's10 (3.31)18.2507
2000's32 (10.60)29.6817
2010's258 (85.43)24.3611
2020's2 (0.66)2.80

Authors

AuthorsStudies
Armstrong, DK; Arranz, JA; Coleman, RL; Fujiwara, K; Gabra, H; Ghamande, SA; González-Martín, A; Hanna, R; Herzog, TJ; Jia, Y; Monk, BJ; Pignata, S; Ramsay, L; Rubio, MJ; Scambia, G; Sehouli, J; Slomovitz, B; Tewari, KS; Ushijima, K; Vergote, IB; Vulsteke, C; Weil, SC; Wenham, RM; Zamagni, C1
Bender, D; Bookman, MA; Chi, DS; Cohn, DE; Friedlander, M; Gershenson, DM; Gray, HJ; Lee, RB; Lichtman, SM; Lovecchio, JL; Menzin, AW; Mutch, DG; Purdy, C; Secord, AA; Sia, TY; Teoh, DG; Tew, WP; Tewari, KS; Van Le, L; Wahner Hendrickson, AE; Wenham, RM1
Alvarez Secord, A; Armstrong, DK; Basen-Engquist, K; Brady, MF; Casey, AC; Chan, JK; Cohn, DE; Coleman, RL; Davidson, SA; DiSilvestro, P; Enserro, D; Fujiwara, K; Herzog, TJ; Huang, HQ; Kim, BG; Kim, JW; Mannel, RS; Nam, JH; Park, SY; Rubin, S; Sabbatini, P; Spirtos, NM; Tewari, KS; Walker, JL1
Brown, JM; Brundage, MD; Cook, A; Embleton, AC; Kaplan, RS; Ledermann, JA; Qian, W; Raja, FA; Stark, DP; Swart, AMW; Velikova, G1
Balega, J; Elattar, A; Kehoe, S; Nevin, J; Phillips, A; Singh, K; Sundar, S1
Armstrong, DK; Ashfaq, R; Basen-Engquist, K; Brady, MF; Chan, JK; Coleman, RL; Davidson, SA; DiSilvestro, P; Fujiwara, K; Herzog, TJ; Huang, H; Kim, BG; Mannel, RS; O'Malley, DM; Rubin, SC; Sabbatini, P; Spirtos, NM; Tewari, KS; Walker, JL1
Birrer, M; Brozick, J; Bshara, W; Edwards, RP; Grabosch, S; Lankes, HA; Lugade, A; Ma, T; Moore, K; Odunsi, K; Omilian, A; Strange, M; Stuckey, AR; Tseng, G; Vlad, A; Walker, JL1
Kang, S; Kim, SH; Lim, MC; Park, SY; Seo, SS; Song, YJ; Yoo, CW; Yoo, HJ1
Bergzoll, C; Eva, L; Jamieson, A; Simcock, B; Sykes, P1
Crim, A; Ding, K; Dvorak, J; Gillen, J; Greenwade, M; Gunderson, C; Moore, K; Rowland, M; Ruskin, R; Walter, A1
Alberts, DS; Angioli, R; Baldelli, E; Dong, T; Gambara, G; Guillen-Rodriguez, JM; Hodge, KA; Liotta, LA; Memo, M; Odicino, F; Pecorelli, SL; Petricoin, EF; Pierobon, M; Ravaggi, A; Sereni, MI1
Boban, T; Boraska Jelavić, T; Brčić, L; Vrdoljak, E1
Chen, Y; Teng, NNH; Westhoff, GL1
Curry, E; Gabra, H; Janczar, S; Nautiyal, J; Paige, AJ; Sun, M; Xiao, Y; Zanini, E1
Fernandes Junior, HJ; Graziani, SR; Kalil Filho, R; Maranhão, RC; Morikawa, AT; Van Eyll, BM; Vital, CG1
Jia, L; Jin, H; Lu, Y; Lv, M; Ming, Y; Yu, Y; Zhao, H; Zhao, N; Zheng, Z; Zhou, J1
Copeland, NG; Hanash, SM; Hashimoto, K; Jenkins, NA; Katayama, H; Kimura, T; Kobayashi, M; Kodama, M; Kodama, T; Mabuchi, S; Newberg, JY; Rangel, R; Sawada, K; Tien, JC; Wei, Z; Yoshihara, K1
Chen, WT; Dombroff, MK; Dong, H; Pearl, ML; Tulley, S; Zhao, Q1
Bonetti, A; Giuliani, J1
Bun, S; Ebata, T; Fujiwara, Y; Kato, T; Kodaira, M; Shimizu, C; Shimoi, T; Shimomura, A; Tamura, K; Yonemori, K; Yoshida, H; Yunokawa, M1
Marth, C; Reimer, D; Zeimet, AG1
Chan, JK; Monk, BJ1
Guo, Q; Huang, S; Li, Z; Liao, Y; Liu, Y; Lu, L; Sun, H; Wang, X; Zhang, Y; Zhao, L1
Aalbers, AGJ; Aaronson, NK; Arts, HJ; de Hingh, IHJT; Hermans, RHM; Kieffer, JM; Koole, SN; Massuger, LFAG; Schagen van Leeuwen, JH; Schreuder, HWR; Sikorska, K; Sonke, GS; Van de Vijver, KK; van der Velden, J; van Driel, WJ; van Tinteren, H; Verwaal, VJ1
Banerjee, S; Chen, J; Colombo, N; Gore, M; Gorla, S; Hirte, H; Kaye, S; Naumann, RW; Oza, A; Poondru, S; Sessa, C; Singh, M; Steinberg, J; Van Tornout, J; Yuen, G1
Bristow, RE; Burger, RA; Eskander, RN; Fujiwara, K; Glaser, GE; Hamilton, CA; Huh, WK; Kauderer, J; Mannel, RS; O'Malley, DM; Rubin, SC; Stephan, JM; Tewari, KS; Ueland, F1
Mandai, M; Matsumura, N; Murakami, K; Nakai, H; Suzuki, A; Takaya, H; Tobiume, T1
Dos Santos Guimarães, I; Dos Santos, DZ; Gimba, ERP; Ladislau-Magescky, T; Rangel, LBA; Silva, IV; Sternberg, C; Tessarollo, NG1
Akbayir, O; Ayhan, A; Celik, H; Cuylan, ZF; Dede, M; Gungor, T; Gungorduk, K; Kuscu, E; Meydanli, MM; Ozgul, N; Sahin, H; Sari, ME1
Hashimoto, H; Kontani, K; Mimura, M; Miyatake, T; Nagamatsu, M; Nishikawa, A; Takeda, M; Yokoi, T1
Chen, GP; Chen, YQ; Hu, JL; Liu, NF; Sun, HY; Yang, Y; Yu, H; Zhu, JQ; Zhu, T1
Chen, H; Dong, W; Hou, Y; Li, B; Lin, M; Lou, G; Xia, B; Zhang, X1
Bodurka, DC; Bookman, MA; Friedlander, M; Geller, M; Glaser, G; Herzog, TJ; Java, JJ; Krivak, TC; Lee, RB; Mutch, DG; O'Malley, DM; Olawaiye, AB; Wenham, RM1
Ghaem-Maghami, S; Jung, Y; Lam, EW; Maher, J; Natoli, M; Parente-Pereira, AC; Smith, JR; Wahba, J; Whilding, LM; Zona, S1
Beck, HM; Fuh, KC; Guo, L; Hagemann, AR; Ilivicky, AR; Lawrence, JA; Lomonosova, E; McCourt, C; Mills, KA; Mutch, DG; Powell, MA; Quinn, JM; Roach, ST; Starks, CM; Thaker, PH1
Hirasawa, T; Iida, T; Ikeda, M; Machida, H; Mikami, M; Shida, M1
Komiyama, S; Kubushiro, K; Kugimiya, T1
DeFazio, A; Francis, J; Friedlander, M; Goss, G; Jordan, S; O'Brien, S; Obermair, A; Quinn, M; Steer, C; Webb, P; Wyld, D1
Castro, C; de León, DC; Gallardo, D; Herrera, LA; López, A; Mendoza, J; Mohar, A; Morales, F; Oñate, LF; Perez, D; Prada, D; Santibáñez, M1
Armstrong, DK; Coleman, RL; Phillips, M; Weil, SC; White, AJ1
Hoffman, RM; Jung, PS; Kim, DY; Kim, JH; Kim, MB; Kim, YM; Kim, YT; Lee, SW; Nam, JH1
Apte, SM; Bou Zgheib, N; Gonzalez-Bosquet, J; Judson, PL; Lancaster, JM; Roberts, WS; Teefey, P; Wenham, RM1
Adank, MA; Burger, CW; de Bock, GH; de Hullu, JA; Gaarenstroom, KN; Kriege, M; Mourits, MJ; Reitsma, W; Rijcken, F; Schmidt, MK; Seynaeve, C; Slangen, BF; van Altena, AM; van Beurden, M; Vasen, HF; Vencken, PM; Zweemer, RP1
Armstrong, DK; Copeland, LJ; Java, J; Landrum, LM; Lanneau, GS; Mathews, CA; Walker, JL1
Bellone, S; Bignotti, E; Buza, N; Cocco, E; Pecorelli, S; Ravaggi, A; Romani, C; Roque, DM; Rutherford, TJ; Santin, AD; Schwartz, PE1
Hu, P; Kang, S; Li, Y; Sun, HY; Wang, N; Zhou, RM1
Bodnar, L; Grala, B; Kozlowski, W; Smoter, M; Stec, R; Szczylik, C; Zieniuk, K1
Chen, KJ; Chen, L; Chen, WY; Chen, X; Jia, YM; Peng, GQ1
Alder, H; Baldassarre, G; Belletti, B; Califano, D; Canzonieri, V; Chiappetta, G; Cirombella, R; Croce, CM; Giglio, S; Losito, S; Lovat, F; Onesti, EC; Pellegrini, P; Pignata, S; Sonego, M; Sorio, R; Stoppacciaro, A; Vecchione, A; Volinia, S; Wernicke, D1
Markman, M2
Dhillon, S1
Greenberg, J; Grisaru, D; Inbar, M; Levy, T; Matcejevsky, D; Pelles, S; Safra, T; Shamai, S; Shpigel, S; Veizman, A1
Graeser, MK; Jaenicke, F; Mahner, S; Mathey, S; Milde-Langosch, K; Müller, V; Trillsch, F; Woelber, L; Zu Eulenburg, C1
Li, D; Yao, X; Zhang, P1
Kubushiro, K; Kurasaki, A; Sakurai, N; Takahashi, K; Taoka, H; Yamamoto, Y1
Bookman, MA; Brady, MF; Burger, RA; Kong, G; Nguyen, HP; Rhee, J; Sovak, MA1
Bean, Y; Beckmann, MW; Beesley, J; Berchuck, A; Brown, R; Camey, ME; Chen, X; Chenevix-Trench, G; Cramer, DW; Cunningham, JM; deFazio, A; Despierre, E; du Bois, A; Ekici, AB; Emmanuel, C; Fasching, PA; Fereday, S; Fridley, BL; Gao, B; Goode, EL; Goodman, MT; Haber, M; Harter, P; Hedditch, EL; Heitz, F; Henderson, MJ; Hogdall, C; Hogdall, E; Jensen, A; Johnatty, SE; Karlan, BY; Kjaer, SK; Lambrechts, S; Law, MH; Lester, J; Levine, DA; Lu, Y; Lurie, G; MacGregor, S; Norris, MD; Paul, J; Pejovic, T; Russell, AJ; Schwaab, I; Shildkraut, J; Terry, KL; Thompson, PJ; Vergote, I; Vierkant, RA; Webb, PM1
Aoki, D; Isonishi, S; Jobo, T; Katsumata, N; Kimura, E; Kodama, S; Michimae, H; Ochiai, K; Sugiyama, T; Takahashi, F; Terauchi, F; Yasuda, M1
Kruitwagen, RF; Massuger, LF; Ottevanger, PB; van de Laar, R; Van Gorp, T; Zusterzeel, PL1
Crivellaro, C; Cuzzocrea, M; Dell'Anna, T; Dolci, C; Fruscio, R; Guerra, L; Messa, C; Milani, R; Signorelli, M; Sina, F1
Barker, J; Burrell, M; Feuer, GA; Lakhi, N; Salmieri, S1
Leary, A; Lhomme, C; Pautier, P; Tazi, Y1
Fujiwara, K; Iwasaki, S; Muraji, M; Nishimura, R; Sudo, T; Ueno, S; Wakahashi, S; Yamaguchi, S1
Lawrie, TA; Morrison, J; Rabbie, R; Thoma, C1
Ahmed, N; Fraser, FW; Kumar, J; McCulloch, DR; Riley, C; Ward, AC1
Walker, JL1
Bagnoli, M; Canevari, S; De Cecco, L; Granata, A; Iorio, E; Mezzanzanica, D; Nicoletti, R; Pisanu, ME; Podo, F; Ricci, A; Tinaglia, V1
da Costa Miranda, V; da Silva Bessa, LR; da Silva, JR; de Freitas, D; de Paula Carvalho, J; de Souza Fêde, ÂB; Del Pilar Estevez Diz, M; Dos Anjos, CH; Filho, EA; Sanchez, FB1
Alvero, AB; Azodi, M; Craveiro, V; Gill, SK; Griffin, B; Holmberg, JC; Joo, WD; Mor, G; Pizzonia, J; Rutherford, T; Silasi, DA; Sumi, NJ; Yang-Hartwich, Y1
Hong, JH; Jin, HM; Kim, JW; Lee, JK; Lee, NW; So, KA; Song, JY1
Cheng, J; Deng, BF; Huang, JM; Lin, Q; Lu, HY; Ma, SQ; Shi, Y; Wang, MM; Wang, W; Zha, X; Zhang, GN; Zhu, Y1
Hay, JW; Mehta, DA1
González Ruiz de la Herrán, F; Haya Palazuelo, J; López de la Manzanara Cano, C; Martín Fernández, J; Padilla Valverde, D; Pascual-Ramírez, J; Sánchez García, S; Villarejo Campos, P1
Brower, SL; Krivak, TC; Leath, CA; Lele, S; Moore, RG; Richard, S; Secord, AA; Tian, C1
Christopoulou, A; Emmanouilidis, C; Georgoulias, V; Kalbakis, K; Kalykaki, A; Koinis, F; Papadimitraki, E; Polyzos, A; Samonis, G; Zafeiriou, Z1
Bodnar, L; Grala, B; Jakobsen, A; Smoter, M; Stec, R; Steffensen, KD; Szczylik, C; Waldstrøm, M1
Chen, X; Dai, H; Qian, Z; Wang, Y; Xu, X; Zhao, Y1
Aoki, Y; Asakura, H; Doi, D; Fujita, K; Honma, S; Kamoi, S; Kato, H; Kodama, S; Konishi, H; Matsushima, T; Nakayama, H; Takeshita, T; Tanaka, K; Yahata, T; Yoneyama, K1
Dowlati, A; Eaton, S; Frasure, H; Fu, P; Fusco, N; Schwandt, A; von Gruenigen, VE; Waggoner, S; Wenham, RM; Wright, JJ1
Cai, M; Gao, J; Hu, Z; Lin, B; Liu, C; Liu, D; Liu, J; Tan, M; Zhang, D1
Benbrook, DM; Ding, K; McMeekin, DS; Moore, KN; Nelson, T; Penaroza, S; Slaughter, KN; Thai, T; Thavathiru, E1
Blansit, K; Chan, JK; Herzog, TJ; Hu, L; Kapp, DS; Kiet, T; Monk, BJ; Yu, X1
Chang, CL; Chen, CP; Cheng, JT; Lee, WL; Seow, KM; Tsui, KH; Wang, PH; Wang, SY; Yang, LW; Yen, MS1
Ansaloni, L; Bogani, G; Coccolini, F; Frigerio, L; Grosso, G; Rossetti, D1
Bratos, R; Chiva, L; González-Martín, A; Márquez, R; Sánchez-Lorenzo, L1
Bae, DS; Bamias, A; Brize, A; Coleman, RL; Fabbro, M; Fujiwara, K; Herzog, TJ; Karlan, BY; Lhommé, C; Marth, C; Monk, BJ; Navale, L; Oaknin, A; Oza, AM; Poveda, A; Provencher, DM; Raspagliesi, F; Ray-Coquard, I; Redondo, A; Richardson, G; Rincón, DG; Tassoudji, M; Vergote, I; Warner, DJ1
Ercoli, A; Fagotti, A; Margariti, PA; Pedone Anchora, L; Petrillo, M; Salutari, V; Scambia, G; Tortorella, L; Zannoni, GF1
Barry-O'Crowley, J; Bates, M; Cooke, AA; Costello, KM; d'Adhemar, CJ; D'Arcy, T; Ffrench, B; Finn, S; Flood, B; Gallagher, MF; Gleeson, N; Haley, K; Hennessy, B; Kernan, N; Martin, CM; McCann, A; Murphy, C; O'Byrne, K; O'Donnell, D; O'Leary, JJ; O'Neill, LA; O'Toole, S; Pennington, S; Sheils, O; Smyth, PC; Spillane, CD; Stordal, B1
Aghajanian, C; DeLair, D; Grisham, RN; Hyman, DM; Iasonos, A; Iyer, G; Sala, E; Zhou, Q1
Braicu, EI; Darb-Esfahani, S; Denkert, C; Fotopoulou, C; Joens, T; Lindhofer, H; Mahner, S; Mellstedt, H; Pietzner, K; Richter, R; Sehouli, J; Woopen, H1
Boere, IA; de Gooyer, D; Goey, SH; Kerkhofs, LG; Kok, TC; Look, M; Onstenk, W; Ottevanger, PB; Ruit, JB; ten Bokkel Huinink, D; Valster, FA; van der Burg, ME; van der Torren, AM; van Doorn, HC; van Reisen, AG; Verweij, J1
Shen, K; Song, Y; Xia, Z; Xin, X; Zhai, X1
Hewidy, M; Shawky, H; Tawfik, H1
Byun, HJ; Kim, BR; Lee, SH; Rho, SB; Seo, SH; Yoon, K1
Chaudhury, S; Gaikwad, SM; Jinager, A; Maheshwari, A; Ray, P; Singh, RK1
Geller, M; Ramakrishnan, S; Rivard, C; Saluja, A; Saluja, M; Schnettler, E; Vogel, RI1
Chen, S; Tai, H; Tong, X; Wang, J; Yang, F; Yang, Y; Yiqin, O1
Cascales-Campos, PA; Feliciangeli, E; Gil, E; Gil, J; González-Gil, A; López, V; Nieto, A; Parrilla, JJ; Parrilla, P; Ruiz-Pardo, J1
Bertrand, M; Colombo, PE; Fabbro, M; Gutowski, M; Labaki, M; Mollevi, C; Mourregot, A; Quenet, F; Rouanet, P; Saint-Aubert, B1
Mannel, RS; Moore, KN; Slaughter, KN1
Cho, H; Kim, JH; Kim, S; Kim, SW; Kim, YT; Lee, M; Nam, EJ1
Chang, MC; Chen, CA; Cheng, WF; Chiang, YC; Hsieh, CY; Kuo, KT; Lin, HP; Lu, TP1
Bruixola, G; Caballero, J; De La Cueva, H; Díaz, R; Domingo, S; Palomar, L; Santaballa, A1
Bonneau, C; Castela, M; Cortez, A; Daraï, E; Geyl, C; Lis, R; Rouzier, R; Touboul, C1
Ansaloni, L; Ballerini, A; Bertoli, P; Busci, LM; Cambria, F; Ceresoli, M; Coccolini, F; D'Incalci, M; Frigerio, L; Grosso, G; Lotti, M; Morosi, L; Pisano, M; Rossetti, D; Zucchetti, M1
Andrade, C; Clark, RM; del Carmen, MG; Esselen, KM; Foley, OW; Hinchcliff, EM; Horowitz, NS; Rauh-Hain, JA; Vargas, RJ; Winograd, D1
Borani, N; Karalök, MA; Keskin, HL; Köse, MF; Özgül, N; Tulunay, HG; Turan, AT; Üreyen, I1
Chang, CH; Chen, CC; Chiu, WT; Chou, CY; Hsu, KF; Huang, SC; Huang, YF; Tsai, HY1
Bismayer, JA; Dudley, BS; Finney, LH; Gian, VG; Hainsworth, JD; Merritt, WM; Thompson, DS; Whorf, RC1
Jansaka, N; Suprasert, P1
Barbolina, MV; Choi, J; Gurler, H; Kajdacsy-Balla, AA; Yu, Y1
Gaikwad, SM; Ray, P; Sakpal, A; Singh, RK; Thakur, B1
Matsumoto, K; Onda, T; Yaegashi, N1
Armstrong, DK; Chan, JK; Herzog, T; Java, JJ; Markman, M; Monk, BJ; Salani, R; Tewari, D1
Amiji, MM; Duan, Z; Feng, Y; Foster, R; Gao, Y; Hornicek, FJ; Mankin, HJ; Shen, JK; Yang, X1
Amler, LC; Bais, C; Choi, Y; Firestein, R; Fu, L; Fuentes, E; Guan, Y; Huw, LY; Lackner, MR; Lu, S; Rabe, C; Ryner, L; Wang, Y; Xiao, Y1
Katsumata, N2
Fukuda, T; Hashiguchi, Y; Ichimura, T; Imai, K; Sumi, T; Teramae, M; Yamauchi, M; Yasui, T1
Li, PL; Xu, A; Zhang, LY; Zhang, XC1
Dandapani, M; Eng, KH; Goldberg, GL; Horwitz, SB; Odunsi, K; Odunsi-Akanji, O; Seagle, BL; Shahabi, S; Yang, CP1
Ozbasar, D; Sakarya, DK; Yetimalar, MH1
Cohen, JG; Li, AJ; Tran, AQ1
Baba, T; Ishikawa, M; Kanato, K; Nakamura, K; Satoh, T; Shibata, T; Takano, M; Tsuda, H; Ushijima, K; Yaegashi, N; Yoshikawa, H1
Anuradha, S; Brand, AH; Donovan, PJ; Friedlander, M; Goh, J; Jordan, SJ; Oehler, MK; Quinn, M; Steer, C; Webb, PM1
Chang, TH; Chen, CC; Chou, CY; Huang, YF; Wu, YH1
Cheng, X; Li, X; Lu, W; Mao, Y; Pan, Q; Wan, X; Xie, X1
Koo, YJ; Lim, KT1
Duk, MJ; Pasker-de Jong, PC; Schreuder, HW; van Vliet, MM1
Cheng, L; Guo, Y; Hu, L; Lv, QL; Qin, CZ; Wu, NY; Zhou, HH1
Beumer, JH; Ivy, SP1
Bandera, EV; Kushi, LH; Lee, VS; Powell, CB; Rodriguez-Rodriguez, L2
Bian, C; Li, L; Yao, K; Yi, T; Zhao, X1
Kumar, L; Patel, S; Singh, N1
Alexander, H; Banerjee, S; Barton, D; Bodla, S; Georgiou, A; Gore, M; Kaye, S; McLachlan, J; Nobbenhuis, M; Seifert, H1
Shi, C; Shuang, T; Wang, D; Wang, M; Zhou, Y1
Bae, DS; Cho, YJ; Choi, CH; Choi, JJ; Do, IG; Hong, JE; Jeon, HK; Kim, BG; Kim, MK; Kim, TJ; Kim, WY; Lee, JW; Lee, SH; Lee, YY; Ryu, JY; Yoon, G1
Bae, T; Choi, JW; Eum, KH; Kim, S; Lee, JW; Weon, KY1
Chang, CF; Chang, MC; Chen, CA; Chen, TC; Cheng, WF; Chiang, YC; Fu, CF; Hsieh, SF; Lin, HW1
Ahn, JS; Ahn, MJ; Kim, HS; Lee, JY; Lee, SH; Lim, SH; Moon, SH; Park, K; Sun, JM1
Bouchard-Fortier, G; Covens, A; Ferguson, SE; Gien, LT; Kupets, R; Pasetka, M; Pulman, K; Rosen, B; Vicus, D; Vyarvelska, I1
Qiang, WA; Tan, W; Wang, SP; Wang, YT; Zhong, ZF1
Ge, G; Niu, L; Ren, Y; Yan, Y; Zhang, W; Zou, Y1
Kim, JH; Lee, EJ; Lee, TJ; Nguyen, TM; Park, J; Park, MS; Shin, IW1
Bae, DS; Byeon, Y; Cho, SK; Cho, YJ; Han, HD; Jeon, HN; Kim, BG; Kim, HS; Lee, JW; Lopez-Berestein, G; Park, YM; Shin, BC; Sood, AK1
Eisenmann, KM; Khaing, M; Pettee, KM; Rubinic, K; Ziske, MA1
Chiantera, V; Cosentino, F; Costantini, B; Fagotti, A; Fanfani, F; Ferrandina, G; Gallotta, V; Gueli Alletti, S; Margariti, PA; Scambia, G; Tortorella, L; Vizzielli, G1
Ezendam, NP; Frielink, LM; Pijlman, BM; Pijnenborg, JM1
Chang Chien, CC; Fu, HC; Huang, CC; Lin, H; Liu, JM; Liu, SC; Ma, YY; Ou, YC; Tsai, CC1
Alvarez, RD; Becker, DA; Bevis, KS; Boone, JD; Gilbert, AL; Huh, WK; Leath, CA; Straughn, JM; Thomas, ED1
Bookman, MA3
Chang, WP; Chang, Y; Chang, YH; Chuang, CM; Lee, WH; Lu, CH; Yen, MS1
Anttila, M; Breda, E; Hanker, LC; Husain, A; Ojeda, B; Pujade-Lauraine, E; Vuylsteke, P; Wang, Y1
Benedetto, C; Canuto, EM; Fishbein, L; Jean, S; Katsaros, D; Li, J; Maxwell, KN; McLane, MW; Mitra, N; Nathanson, KL; Tanyi, JL; Wubbenhorst, B; Zhang, L1
Amadio, G; Di Stefano, MG; Fagotti, A; Ferandina, G; Paris, I; Petrillo, M; Salutari, V; Scambia, G1
Bayar, A; Bereder, JM; Ferron, G; Glehen, O; Gouy, S; Le Deley, MC; Marchal, F; Morice, P; Pomel, C; Quenet, F1
Chang, CL; Chen, JR; Chen, TC; Chien, HJ; Huang, CY; Wang, KL; Weng, CS; Yang, YC1
Arévalo-Pérez, J; Barceló, F; Cascales-Campos, P; Gil, E; Gil, J; López-López, V; Nieto, A; Parrilla, P1
Liu, CC; Lu, Y; Tang, H; Wang, H; Zhu, J1
Hiramatsu, Y; Masuyama, H; Nakamura, K; Nobumoto, E1
Otsuka, I; Shoji, K1
Chi, DS; Gardner, GJ; Iasonos, A; Kelly, A; Long Roche, K; Mueller, JJ; O'Cearbhaill, RE; Sonoda, Y; Zhou, Q; Zivanovic, O1
Choi, KU; Do, KH; Kim, J; Kim, KH; Moon, Y; Park, SH1
Alvarez Secord, A; Armstrong, DK; Cohn, DE; Copeland, LJ; Garcia-Soto, AE; Java, JJ; Lele, SB; Nieves Neira, W; Pearson, JM; Tewari, KS; Walker, JL1
Bamias, A; Chmielowska, E; Colombo, N; Davidenko, I; DeCensi, A; Gadducci, A; González-Martín, A; Hegg, R; Joly, F; Korach, J; Martin, N; Mendiola, C; Oza, AM; Pautier, P; Robb, S; Selle, F; Zamagni, C; Zvirbule, Z1
Bottoni, C; Costantini, B; Fagotti, A; Gallotta, V; Gueli Alletti, S; Nardelli, F; Petrillo, M; Quagliozzi, L; Scambia, G; Vizzielli, G1
Bell, J; Chan, JK; Fuh, K; Herzog, T; Java, JJ; Kapp, DS; Monk, BJ; Young, R1
Kristeleit, R; Ledermann, JA; MacDonald, N; Marchetti, C; McCormack, M; Mould, T; Olaitan, A; Widschwendter, M1
Ataseven, B; du Bois, A; Harter, P; Heitz, F; Hengsbach, A; Kurzeder, C; Prader, S; Schneider, S; Sporkmann, M; Traut, A1
Artioli, G; Baldoni, A; Bergamini, A; Breda, E; Cannella, L; Cecere, SC; Colombo, N; Daniele, G; Ferrandina, G; Floriani, I; Greggi, S; Lo Re, G; Lorusso, D; Maltese, G; Nicoletto, MO; Perrone, F; Piccirillo, MC; Pignata, S; Raspagliesi, F; Salutari, V; Scambia, G; Signoriello, S; Tognon, G1
Kang, SB; Kim, YM; Kim, YT; Lee, SW1
Amant, F; de Haan, J; Fruscio, R; Mhallem, M; Van Calsteren, K; Verheecke, M1
Bae, DS; Cho, WC; Cho, YJ; Choi, CH; Choi, JJ; Choi, YL; Heo, EJ; Hong, JE; Jeon, HK; Kim, BG; Kim, TJ; Lee, JW; Lee, YY; Oh, DY; Park, WY; Song, SY1
Seagle, BL; Shahabi, S1
Decedue, C; Niu, F; Rajewski, RA; Roby, KF; Subramaniam, B; Terranova, PF1
Ambrosone, CB; Armstrong, D; Baysal, BE; Darcy, KM; DeLoia, JA; Gallion, H; Krivak, TC; Tian, C1
Breda, E; Cognetti, F; Gebbia, V; Lorusso, D; Morabito, A; Perrone, F; Pignata, S; Pisano, C; Savarese, A; Scambia, G; Scollo, P; Signoriello, G; Sorio, R; Vernaglia Lombardi, A1
Baba, T; Barnett, JC; Berchuck, A; Chang, JT; Fujii, S; Gray, JW; Gusberg, AH; Huang, Z; Kuo, WL; Lee, PS; Matsumura, N; Mori, S; Murphy, SK; Whitaker, RS1
du Bois, A; Harter, P; Huober, J; Loibl, S; Pfisterer, J; Reichardt, VL; Stopfer, P; Wimberger, P1
Ino, K; Kajiyama, H; Kikkawa, F; Mizutani, S; Nawa, A; Shibata, K1
Cicchillitti, L; Della Corte, A; Di Michele, M; Donati, MB; Ferlini, C; Marcone, S; Rotilio, D; Scambia, G1
Bilici, A; Dane, F; Gumus, M; Salepci, T; Salman, T; Seker, M; Turan, C; Unal, O; Ustaalioglu, BB; Yaylaci, M1
Hur, SY; Kim, JH; Kim, SJ; Lee, JM; Lee, KH; Lee, SH; Lee, YS; Park, YG; Ryu, KS1
Liu, P; Wang, A; Yang, M; Zhang, B; Zhang, X1
Coch, C; Eckhardt, M; Hartmann, G; Kübler, K; Kuhn, W; Pölcher, M; Rudlowski, C; Wolfgarten, M1
Bast, RC; Brown, GL; Jones, MR; Kavanagh, JJ; Levenback, CF; Meng, L; Moore, CL; Ramirez, PT; Wolf, JL1
Campbell, NE; Greenaway, J; Henkin, J; Moorehead, RA; Petrik, J1
Cicchillitti, L; Della Corte, A; Di Michele, M; Donati, MB; Rotilio, D; Scambia, G1
Bagnato, A; Cianfrocca, R; Di Castro, V; Natali, PG; Rosanò, L; Spinella, F1
Liu, J; Matulonis, UA1
Aletti, GD; Hartmann, LC1
Zorn, KK1
Ahn, EH; Eno, ML; Im, DD; Matsuo, K; Rosenshein, NB; Shahzad, MM; Sood, AK1
Andreopoulou, E; Blank, S; Borgato, L; Boyd, L; Curtin, J; Levinson, B; Muggia, F; Pothuri, B; Safra, T; Tiersten, A1
Cartledge, D; Godwin, AK; Kouadio, A; Zhang, H1
Berkowitz, RS; Gao, Z; Garner, EI; Litkouhi, B; McClane, B; Mok, SC; Welch, WR; Xu, X; Zeng, Q1
Clamp, AR; Evans, S; Griffiths, RW; Hasan, J; Jayson, GC; Kumaran, GC; Mitchell, CL; Welch, RS; Zee, YK1
Bassett, R; Coleman, RL; Dos Reis, R; Harrell, R; Milam, MR; Ramirez, PT; Tao, X1
Chicharoen, S; ImAim, C; Liabsuetrakul, T; Reungrairatanaroj, P1
Aoki, D; Arao, T; Chiyoda, T; Kataoka, F; Nishimura, S; Nishio, K; Nomura, H; Susumu, N; Tsuda, H1
Backes, FJ; Cohn, DE; Copeland, LJ; Eisenhauer, EL; Fowler, JM; McCann, GA; O'Malley, DM; Rheaume, PS; Richardson, DL; Salani, R1
Amin, MS; Eisenhauer, EA; Hoskins, PJ; Islam, S; O'Brien, AM; Pelletier, LB; Squire, JA; Tu, D; Weberpals, JI1
Faught, W; Fung, MF; Hopkins, L; Jolicoeur, L; Latifah, H; Le, T; Weberpals, J1
Azodi, M; Baker, L; Husband, A; Kelly, MG; Mor, G; O'Malley, DM; Rutherford, TJ; Schwartz, PE1
Atkinson, MA; Ferguson, SE; Helpman, L; Le, L; Mackay, H; Mackean, M; Rana, A; Rogerson, A1
Echarri Gonzalez, MJ; Green, R; Muggia, FM1
Brady, MF; Cohn, DE; Degeest, K; Hanjani, P; Hiura, M; Kohn, EC; Lee, R; Mannel, RS; Michael, H; Monk, BJ1
Cui, H; Kong, L; Li, X; Wang, J; Wang, S; Wei, L; Xu, Q; Zhao, Y1
Canuto, EM; Katsaros, D; Lu, L; Rutherford, T; Scarampi, L; Schwartz, P; Yu, H1
Fauci, JM; Frederick, PJ; Kilgore, LC; Schneider, KE; Straughn, JM; Subramaniam, A; Whitworth, JM; Zhang, B1
Farris, C; Krivak, TC; Lesnock, JL; Markman, M; Smith, KJ1
Armstrong, DK; Chernofsky, MR; Farley, JH; Hamilton, CA; Krivak, TC; Markman, M; Maxwell, GL; Miller, A; Miller, C; Ozols, RF; Rose, GS; Stany, MP1
Catot, S; Cervantes, A; Chiva, L; de Juan, A; Del Campo, JM; García, Y; García-Donas, J; González-Martín, A; Martínez, S; Oaknin, A; Ponce, J; Poveda, A; Redondo, A; Roda, D1
Antsaklis, A; Bamias, A; Dimopoulos, MA; Haidopoulos, D; Karadimou, A; Rodolakis, A; Sotiropoulou, M; Soupos, N; Thomakos, N; Zagouri, F1
Han, MH; Hwang, JH; Kang, S; Kim, JH; Kong, SY; Lim, MC; Park, SY; Seo, SS; Yoo, CW; Yoo, HJ1
Foretová, L; Fridrichová, P; Laco, J; Melichar, B; Papajík, T; Simkovič, M1
Griffin, CL; Hirte, H; Ledermann, JA; Parmar, MK; Qian, W; Raja, FA; Swart, AM1
Ardisson, P; Asmane, I; Bajard, A; Bergerat, JP; Coeffic, D; Dufresne, A; Guastalla, JP; Kurtz, JE; Labidi Galy, I; Meeus, P; Moullet, I; Ray-Coquard, I; Tredan, O; Vincent, L1
Burkholder, TL; Chen, MD; Gill, JF; Gordon, AN; Hines, J; Homesley, HD; Janicek, MF; Lim, PC; McMeekin, S; Obasaju, CK; Orlando, M; Tai, DF; Teneriello, M; Vaccarello, L; Wang, Y; Zhao, L1
Antsaklis, A; Bamias, A; Dimopoulos, MA; Haidopoulos, D; Kakoyianni, K; Kostouros, E; Rodolakis, A; Sakellariou, K; Sotiropoulou, M; Thomakos, N; Trachana, P; Vlahos, G; Zagouri, F1
Aghajanian, CA; Bell-McGuinn, KM; Gerst, SR; Grabon, DM; Hensley, ML; Iasonos, A; Konner, JA; Pezzulli, SD; Sabbatini, PJ; Spriggs, DR; Tew, WP; Thaler, H1
Brennan, D; Fitzpatrick, P; Furlong, F; Gallagher, M; Maguire, A; Martin, C; McCann, A; McGettigan, P; McGoldrick, A; McGrogan, B; O'Grady, A; O'Leary, J; O'Toole, S; Phelan, S; Prencipe, M; Sheils, O; W Kay, E1
Beriwal, S; Edwards, RP; Krivak, TC; Lesnock, JL; McBee, WC; Richard, SD; Skaznik-Wikiel, ME; Zorn, KK1
Kim, CW; Kim, E; Kim, YB; Lee, S; Oh, YK; Park, DE; Shim, G; Yu, YH1
Aoki, D; Jobo, T; Katsumata, N; Kumagai, S; Michimae, H; Ochiai, K; Shoji, T; Sugiyama, T; Terauchi, F; Yasuda, M1
Bellone, S; Bignotti, E; Boeke, M; Cristea, MC; Deng, Y; Glasgow, M; Katsaros, D; Keane, FK; Lindner, R; Lu, L; Muller, RU; Nallur, S; Neuhausen, SL; Paranjape, T; Pecorelli, S; Ratner, ES; Ravaggi, A; Rutherford, TJ; Sand, S; Santin, AD; Schwartz, PE; Slack, FJ; Steele, L; Tassi, RA; Weidhaas, JB; Weitzel, JN; Yao, X; Yu, H; Zelterman, D1
Fujiwara, K; Goto, T; Hasegawa, K; Iwasa, N; Kurosaki, A; Nagao, S; Nishikawa, T; Ohishi, R1
Birrer, MJ; Boente, M; Bookman, MA; Brady, MF; Burger, RA; Fleming, GF; Fowler, J; Greer, BE; Homesley, HD; Huang, H; Liang, SX; Mannel, RS; Monk, BJ1
Beale, P; Carey, MS; Cervantes, A; Collinson, F; du Bois, A; Essapen, S; Gourley, C; Kimmig, R; Kristensen, G; Kurzeder, C; Ledermann, JA; Leminen, A; Lortholary, A; Mirza, MR; Oza, AM; Parmar, MK; Perren, TJ; Pfisterer, J; Plante, M; Pujade-Lauraine, E; Qian, W; Sehouli, J; Selle, F; Stähle, A; Stark, D; Swart, AM1
Armstrong, DK; Birrer, M; Bookman, MA; Darcy, KM; Deloia, J; Dhir, R; Krivak, TC; Muggia, F; Niedernhofer, LJ; Rubatt, JM; Tian, C1
Jeon, HW; Jeon, YT; Kim, H; Kim, K; Kim, YB; No, JH1
Copeland, LJ; Richardson, DL; Seamon, LG1
Hellström, I; Hellström, KE; Wei, H1
Boran, N; Celik, B; Hizli, D; Isikdogan, Z; Karabuk, E; Kose, MF; Tulunay, G; Turan, T; Yilmaz, S1
Li, XP; Wang, JL; Wang, SJ; Wei, LH; Xu, QY; Zhao, Y1
Baumann, K; Belau, A; Burges, A; Canzler, U; du Bois, A; Gropp-Meier, M; Huober, J; Kreienberg, R; Meier, W; Rau, J; Richter, B; Schmalfeldt, B; Schröder, W; Sehouli, J; Stähle, A; Wimberger, P; Wollschlaeger, K1
Boere, IA; van der Burg, ME1
Kroep, JR1
Azodi, M; Glasgow, MA; Rutherford, TJ; Santin, AD; Schwartz, PE; Silasi, DA; Yu, H1
Bassi, A; Belotti, D; Castiglioni, V; Cesca, M; Decio, A; Giavazzi, R; Oliva, P; Pesenti, E; Scanziani, E1
Chang, QY; Li, M; Li, XG; Li, YF; Liu, J; Song, PP; Tian, HM; Wang, XB; Wu, LY; Zhang, W; Zhao, D1
Chen, Y; Liu, N; Zhao, J; Zhou, C1
Furuya, K; Goto, T; Kato, M; Kita, T; Kudoh, K; Miyamoto, M; Sasaki, N; Takano, M; Watanabe, A; Yoshikawa, T1
Bast, RC; Jia, L; Li, X; Liu, J; Mercado-Uribe, I; Ye, Y; Zhang, S1
Lichtman, SM; Power, DG; Teo, MY; Tew, WP1
Lowe, MP; Schwartzberg, LS; Stepanski, EJ; Tillmanns, TD; Walker, MS1
Li, H; Li, J; Liu, G; Yin, D; Zhang, J; Zhang, S; Zhang, W; Zhao, J1
Abdulkadir, L; Amant, F; Berteloot, P; Cadron, I; Despierre, E; Leunen, K; Neven, P; Vergote, I1
Aneke, H; Curtin, NJ; Edmondson, RJ; Elattar, A; Maxwell, P; McCluggage, WG; Mukhopadhyay, A; Plummer, ER; Quinn, JE; Soohoo, S; Uzir, B1
Li, GT1
Auranen, A; Carpén, O; Grénman, S; Hynninen, J; Lavonius, M; Oksa, S1
Butler-Manuel, S; Essapen, S; Larbi, E; Madhuri, K; Michael, A; Tailor, A1
Liu, P; Mao, HL; Pang, Y; Wang, Y; Yang, F; Zhang, X; Zheng, J1
Duan, Z; Hu, P; Yue, Y; Zhou, X1
Bagnato, A; Baumann, K; Cognetti, F; Colombo, N; Harter, P; Mari, E; McIntosh, S; Nathan, F; Pemberton, K; Savarese, A; Scambia, G; Sehouli, J; Sorio, R; Wimberger, P1
Cao, Y; Han, Y; Huang, H; Qu, L; Shou, C; Xiao, Z; Zhang, W1
Chang, MC; Chen, CA; Chen, PJ; Cheng, WF; Chiang, YC; Hsieh, CY; Wu, MM1
Bickel, LE; Connolly, DC; Do, TV; Ecsedy, JA; Godwin, AK; Golemis, EA; Howe, C; Hua, X; Klein-Szanto, AJ; Litwin, S; Maglaty, M; O'Brien, SW; Pathak, HB; Schilder, RJ; Xiao, F1
Asai, M; Asai, N; Enomoto, A; Horio, M; Kato, T; Kikkawa, F; Mii, S; Murakumo, Y; Shibata, K; Takahashi, M1
Chu, P; Ghatage, P; Glaze, S; Nation, J; Nelson, G; Teitelbaum, L1
Chen, L; Gong, L; Liang, L; Lin, F; Liu, N; Pan, S; Yan, X; Zhang, Q; Zhao, H; Zheng, F1
Ahiskali, R; Celikel, T; Ceyhan, BB; Duman, D; Duman, DG1
Cruickshank, ME; Delaney, E; Hutcheon, AW; McNally, OM; Parkin, DE; Petty, RD1
Lane, SR; Ross, GA; ten Bokkel Huinink, W1
Baba, T; Goto, M; Nonogaki, T; Tamai, A; Ueda, M; Utsunomiya, Y1
Bolis, G; Cipriani, S; Conta, E; Franchi, M; Guarnerio, P; Mangili, G; Melpignano, M; Parazzini, F; Polverino, G; Presti, M; Raspagliesi, F; Richiardi, G; Scarfone, G; Tateo, S; Villa, A1
Apolone, G; Buda, A1
Cosio, S; Cristofani, R; Frassi, E; Fuso, L; Gadducci, A; Landoni, F; LaPresa, MT; Maggino, T; Maggioni, A; Sartori, E; Zola, P1
Geisler, JP; Manahan, KJ; Wiemann, MC1
Akçay, T; Alademir, Z; Arvas, M; Aydinli, K; Demirkiran, F; Dinçer, Y; Kösebay, D1
Adams, JM; Beaudoin, B; Bouillet, P; Degenhardt, K; Nelson, DA; Nieves-Neira, W; Tan, TT; Villunger, A; White, E1
Kietpeerakool, C; Srisomboon, J; Suprasert, P1
Burges, A; du Bois, A; Gropp, M; Harter, P; Huober, J; Pfisterer, J; Schade-Brittinger, C; Schmalfeldt, B; Staehle, A; Wollschlaeger, K1
DeNardo, G; DeNardo, S; Lamborn, K; Miers, L; Natarajan, A; Richman, C; Yuan, A1
Bae, DS; Kim, BG; Lee, JH; Lee, JW; Lee, SJ; Park, CS1
Gregoire, V; Machiels, JP; Pierard, S; Weynand, B1
Brown, JV; Goldstein, BH; Graham, C; Hu, JC; Markman, M; Micha, JP; Rettenmaier, MA1
Camara, O; Fedders, M; Hartmann, M; Kath, R; Oelschläger, H; Schneider, A1
Dragounová, E; Dvorák, J; Hyspler, R; Kalábová, H; Melichar, B; Tichá, A1
Katsaros, D; Mor, G; Puopolo, M; Rigault de la Longrais, IA; Rutherford, TJ; Schwartz, P; Smith, S; Su, D; Yu, H1
Ferrell, B; Leong, L; Lowe, T1
Colombo, N; Fossati, R; Fruscio, R; Garbi, A; Ieda', N; Lissoni, AA; Mangioni, C; Torri, V1
Capizzi, E; De Iaco, P; Fiorentino, M; Gabusi, E; Grigioni, AD; Rosati, M; Zamagni, C1
Plaxe, SC1
Hurwitz, HI; McGuire, WP1
Burkhart, CA; Haber, M; Horwitz, SB; Kavallaris, M; Kuo, DY; Norris, MD; Regl, DL1
Elbendary, A; Herzog, TJ; Mutch, DG; Rader, JS; Swisher, EM1
Benito, D; Casado, A; Cervantes, A; del Campo, JM; Escobedo, A; Massuti, B; Mendiola, C; Moyano, A; Ojeda, B; Poveda, A1
Aravantinos, G; Athanassiadis, A; Bafaloukos, D; Bamia, C; Fountzilas, G; Karphathios, S; Kosmidis, P; Papakostas, P; Pavlidis, N; Skarlos, DV; Stathopoulos, GP1
Abu-Rustum, NR; Aghajanian, C; Barakat, RR; Fennelly, D; Shapiro, F; Spriggs, D1
Ozols, RF1
Cain, JM; Figge, D; Goff, BA; Greer, B; Seewaldt, VL; Tamimi, H1
Cohen, P; de Leon, CG; Edwards, CL; Finnegan, MB; Forman, A; Freedman, RS; Hord, M; Kavanagh, JJ; Kim, EE; Kudelka, AP; Tresukosol, D; Varma, D; Verschraegen, CF1
Kuwahara, M; Motohiro, A; Takahashi, N; Tsukamoto, S; Ueda, H1
Fracasso, PM1
Bolis, G; Carmichael, J; Coleman, R; Davidson, N; Fields, SZ; Gordon, A; Gore, M; Héron, JF; Malfetano, J; Malmström, H; Ross, G; Scarabelli, C; Spaczynski, M; ten Bokkel Huinink, W; Vennin, P1
Favaudon, V; Hennequin, C1

Reviews

28 review(s) available for paclitaxel and Epithelial Neoplasms

ArticleYear
Front-line therapy of advanced epithelial ovarian cancer: standard treatment.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Nov-01, Volume: 28, Issue:suppl_8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic

2017
Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Nov-01, Volume: 28, Issue:suppl_8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Cyclophosphamide; Female; Humans; Infusions, Parenteral; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic

2017
Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer.
    Gynecologic oncology, 2013, Volume: 131, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Practice Guidelines as Topic

2013
Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2013, Volume: 27, Issue:4

    Topics: Adult; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Evidence-Based Medicine; Fallopian Tube Neoplasms; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A

2013
Ovarian pulmonary-type small cell carcinoma: case report and review of the literature.
    International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists, 2013, Volume: 32, Issue:5

    Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Neuroendocrine; Carcinoma, Ovarian Epithelial; Carcinoma, Small Cell; Carrier Proteins; Female; Humans; Keratins; Lung; Middle Aged; Neoplasms, Glandular and Epithelial; Neural Cell Adhesion Molecules; Ovarian Neoplasms; Paclitaxel; Tomography, X-Ray Computed; Ubiquitin-Protein Ligases

2013
Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.
    The Cochrane database of systematic reviews, 2013, Oct-21, Issue:10

    Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Drug Administration Schedule; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Randomized Controlled Trials as Topic

2013
Intraperitoneal chemotherapy requires expertise and should be the standard of care for optimally surgically resected epithelial ovarian cancer patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24 Suppl 10

    Topics: Carcinoma, Ovarian Epithelial; Cisplatin; Disease-Free Survival; Female; Humans; Infusions, Parenteral; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Standard of Care; Treatment Outcome

2013
Intraperitoneal chemotherapy in advanced epithelial ovarian cancer: a survey.
    Archives of gynecology and obstetrics, 2014, Volume: 290, Issue:3

    Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Survival Analysis

2014
First-line and maintenance therapy for ovarian cancer: current status and future directions.
    Drugs, 2014, Volume: 74, Issue:8

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors

2014
Anti-angiogenic therapy versus dose-dense paclitaxel therapy for frontline treatment of epithelial ovarian cancer: review of phase III randomized clinical trials.
    Current oncology reports, 2014, Volume: 16, Issue:11

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic

2014
Maintenance chemotherapy in the management of epithelial ovarian cancer.
    Cancer metastasis reviews, 2015, Volume: 34, Issue:1

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Maintenance Chemotherapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines

2015
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
    Japanese journal of clinical oncology, 2015, Volume: 45, Issue:5

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids

2015
Dose-dense approaches to ovarian cancer treatment.
    Current treatment options in oncology, 2015, Volume: 16, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis

2015
Novel directions in adjuvant chemotherapy for early stage epithelial ovarian cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Female; Fertility Preservation; Humans; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel

2015
Optimal primary therapy of ovarian cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality Improvement

2016
Ovarian cancer in pregnancy.
    Best practice & research. Clinical obstetrics & gynaecology, 2017, Volume: 41

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Female; Gestational Age; Humans; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Patient Preference; Pregnancy; Pregnancy Complications, Neoplastic

2017
Syngeneic mouse model of epithelial ovarian cancer: effects of nanoparticulate paclitaxel, Nanotax.
    Advances in experimental medicine and biology, 2008, Volume: 622

    Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drug Delivery Systems; Female; Humans; Injections, Intralesional; Injections, Intraperitoneal; Mice; Nanoparticles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Transplantation, Isogeneic

2008
New advances in ovarian cancer.
    Oncology (Williston Park, N.Y.), 2010, Volume: 24, Issue:8

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Female; Humans; Infusions, Parenteral; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Poly Adenosine Diphosphate Ribose; Proteins

2010
Intraperitoneal drug delivery for ovarian cancer: why, how, who, what, and when?
    Oncology (Williston Park, N.Y.), 2011, Volume: 25, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Cyclophosphamide; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel

2011
Dose-dense therapy is of benefit in primary treatment of ovarian cancer? In favor.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22 Suppl 8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome

2011
First-line chemotherapy in epithelial ovarian cancer.
    Clinical obstetrics and gynecology, 2012, Volume: 55, Issue:1

    Topics: Adenocarcinoma, Mucinous; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Topotecan; Vascular Endothelial Growth Factor A

2012
Evolution of the Gynecologic Oncology Group protocols in the treatment of epithelial ovarian cancer.
    Clinical obstetrics and gynecology, 2012, Volume: 55, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Female; Humans; Laparotomy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyglutamic Acid; Second-Look Surgery

2012
Review of dose-intense platinum and/or paclitaxel containing chemotherapy in advanced and recurrent epithelial ovarian cancer.
    Current pharmaceutical design, 2012, Volume: 18, Issue:25

    Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Recurrence

2012
Chemotherapy for ovarian cancer: an evidence-based approach.
    Minerva ginecologica, 2004, Volume: 56, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Paclitaxel; Time Factors

2004
Quality-of-life issues in the management of epithelial ovarian cancer.
    Current treatment options in oncology, 2007, Volume: 8, Issue:6

    Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Taxoids

2007
Primary chemotherapy in epithelial ovarian cancer.
    Obstetrics and gynecology clinics of North America, 1994, Volume: 21, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel

1994
Future directions in the chemotherapy of ovarian cancer.
    Seminars in oncology, 1997, Volume: 24, Issue:5 Suppl 15

    Topics: Administration, Oral; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Europe; Female; Forecasting; Gemcitabine; Humans; Injections, Intraperitoneal; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Time Factors; Topotecan; Vinblastine; Vinorelbine

1997
Overcoming drug resistance in ovarian carcinoma.
    Current oncology reports, 2001, Volume: 3, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Maximum Tolerated Dose; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome

2001

Trials

62 trial(s) available for paclitaxel and Epithelial Neoplasms

ArticleYear
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
    Gynecologic oncology, 2023, Volume: 170

    Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Recurrence

2023
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
    The New England journal of medicine, 2019, 11-14, Volume: 381, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Reoperation; Survival Analysis

2019
Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.
    Cancer, 2017, Jul-15, Volume: 123, Issue:14

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Remission Induction

2017
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2017, Volume: 18, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Young Adult

2017
Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma.
    Medical oncology (Northwood, London, England), 2017, Volume: 34, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Lipids; Nanoparticles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols

2017
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
    The New England journal of medicine, 2018, 01-18, Volume: 378, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Hyperthermia, Induced; Intention to Treat Analysis; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Survival Analysis

2018
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
    Gynecologic oncology, 2018, Volume: 149, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Pyrazines; Treatment Outcome; Young Adult

2018
Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecologic oncology, 2018, Volume: 149, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Young Adult

2018
Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.
    Gynecologic oncology, 2018, Volume: 151, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome

2018
Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
    Gynecologic oncology, 2013, Volume: 129, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids

2013
Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study.
    European journal of drug metabolism and pharmacokinetics, 2014, Volume: 39, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Ovarian Epithelial; Chromatography, High Pressure Liquid; Cisplatin; Drug Administration Schedule; Drug Interactions; Female; Half-Life; Humans; Infusions, Intravenous; Liver; Metabolic Clearance Rate; Models, Biological; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Saponins; Triterpenes

2014
Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.
    Gynecologic oncology, 2013, Volume: 131, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Neoplasms, Glandular and Epithelial; Observer Variation; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Radiography; Single-Blind Method

2013
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Proportional Hazards Models

2013
Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG).
    Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prospective Studies; Salvage Therapy; Taxoids

2014
A phase II study of paclitaxel and carboplatin with a biweekly schedule in patients with epithelial ovarian cancer: Gynecologic Cancer Network trial.
    Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, 2014, Volume: 81, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Treatment Outcome

2014
Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
    Investigational new drugs, 2014, Volume: 32, Issue:4

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Niacinamide; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Sorafenib

2014
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Aged; Angiogenesis Inhibitors; Angiopoietin-1; Angiopoietin-2; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Double-Blind Method; Edema; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Recombinant Fusion Proteins; Withholding Treatment

2014
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2014, Volume: 24, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Young Adult

2014
Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Europe; Fatigue; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Middle Aged; Nausea; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Time Factors; Treatment Outcome; Vomiting; Young Adult

2014
Weekly dose-dense paclitaxel and carboplatin in recurrent ovarian carcinoma: a phase II trial.
    Journal of the Egyptian National Cancer Institute, 2014, Volume: 26, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Treatment Outcome

2014
Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute.
    Cancer medicine, 2015, Volume: 4, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Niacinamide; Ovarian Neoplasms; Paclitaxel; Phenylurea Compounds; Sorafenib; Survival Analysis; Treatment Outcome

2015
A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Male; Middle Aged; Neoplasms, Glandular and Epithelial; Paclitaxel; Prospective Studies; Thymus Neoplasms

2015
Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 59

    Topics: Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Body Image; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Length of Stay; Middle Aged; Neoplasms, Glandular and Epithelial; Operative Time; Ovarian Neoplasms; Paclitaxel; Postoperative Complications; Quality of Life; Young Adult

2016
Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer.
    Gynecologic oncology, 2016, Volume: 142, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Topotecan

2016
Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer.
    Gynecologic oncology, 2016, Volume: 142, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Hyperthermia, Induced; Maintenance Chemotherapy; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel

2016
Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2017, Volume: 27, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Young Adult

2017
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial.
    Gynecologic oncology, 2017, Volume: 144, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Cytoreduction Surgical Procedures; Feasibility Studies; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel

2017
An open-label, multicenter, phase I trial of a cremophor-free, polymeric micelle formulation of paclitaxel combined with carboplatin as a first-line treatment for advanced ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3016).
    Journal of gynecologic oncology, 2017, Volume: 28, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Micelles; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Republic of Korea

2017
Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jul-20, Volume: 26, Issue:21

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease-Free Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide

2008
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
    Oncology, 2009, Volume: 76, Issue:1

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Survival Analysis; Treatment Outcome

2009
A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Dose-Response Relationship, Drug; Female; Genital Neoplasms, Female; Humans; Indoles; Maximum Tolerated Dose; Middle Aged; Neoplasms, Glandular and Epithelial; Paclitaxel; Treatment Outcome

2010
Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer.
    Journal of surgical oncology, 2010, Feb-01, Volume: 101, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Case-Control Studies; Chemotherapy, Adjuvant; Feasibility Studies; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Treatment Outcome

2010
Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Early Termination of Clinical Trials; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Niacinamide; Ovarian Neoplasms; Paclitaxel; Phenylurea Compounds; Pyridines; Sorafenib

2010
Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer.
    Journal of hematology & oncology, 2010, Mar-11, Volume: 3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Glutathione; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Polyethylene Glycols; Survival Analysis; Treatment Failure

2010
Weekly paclitaxel with intermittent imatinib mesylate (Gleevec): tolerance and activity in recurrent epithelial ovarian cancer.
    Anticancer research, 2010, Volume: 30, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Piperazines; Pyrimidines; Salvage Therapy

2010
Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Isoflavones; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum Compounds; Taxoids; Treatment Failure; Treatment Outcome

2011
A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study.
    Gynecologic oncology, 2011, Volume: 122, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Treatment Outcome

2011
The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study.
    Gynecologic oncology, 2011, Volume: 122, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Survival Rate

2011
Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a GEICO study.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Drug Administration Schedule; Feasibility Studies; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Outpatients; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Spain; Treatment Outcome

2011
Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.
    British journal of cancer, 2011, Sep-27, Volume: 105, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines; Survival Rate; Treatment Outcome

2011
Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.
    Gynecologic oncology, 2011, Volume: 123, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Induction Chemotherapy; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Young Adult

2011
Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Dec-10, Volume: 29, Issue:35

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Pilot Projects

2011
Does severe anemia caused by dose-dense paclitaxel-Carboplatin combination therapy have an effect on the survival of patients with epithelial ovarian cancer? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Hemoglobins; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies

2011
Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2012, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Drug Administration Schedule; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome

2012
Incorporation of bevacizumab in the primary treatment of ovarian cancer.
    The New England journal of medicine, 2011, Dec-29, Volume: 365, Issue:26

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Survival Analysis; Young Adult

2011
A phase 3 trial of bevacizumab in ovarian cancer.
    The New England journal of medicine, 2011, Dec-29, Volume: 365, Issue:26

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Survival Analysis

2011
Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV.
    Gynecologic oncology, 2012, Volume: 126, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Piperidines; Prospective Studies; Pyridines; Survival Analysis; Young Adult

2012
Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.
    Gynecologic oncology, 2013, Volume: 128, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Treatment Outcome

2013
Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival.
    Cancer research, 2012, Nov-15, Volume: 72, Issue:22

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; DNA Breaks, Double-Stranded; Enzyme Inhibitors; Female; Homologous Recombination; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors

2012
Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy?
    Gynecologic oncology, 2013, Volume: 128, Issue:2

    Topics: Abdominal Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel

2013
A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-O
    Gynecologic oncology, 2013, Volume: 130, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Placebos; Pyrrolidines; Young Adult

2013
Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Disease Progression; Drug Administration Schedule; Female; Humans; Incidence; Infusions, Intravenous; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Sensitivity and Specificity; Survival Analysis; Topotecan

2004
Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Feb-15, Volume: 22, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Survival Rate

2004
Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery.
    The journal of obstetrics and gynaecology research, 2006, Volume: 32, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cisplatin; Disease-Free Survival; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel

2006
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis.
    British journal of cancer, 2008, Feb-26, Volume: 98, Issue:4

    Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cisplatin; Cystadenocarcinoma, Serous; Epirubicin; Female; Follow-Up Studies; Humans; Ifosfamide; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Survival Rate; Time Factors

2008
Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer.
    Diagnostic molecular pathology : the American journal of surgical pathology, part B, 2008, Volume: 17, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Disease Progression; DNA, Neoplasm; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Survival Analysis; Treatment Outcome

2008
Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
    Gynecologic oncology, 1997, Volume: 66, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Survival Analysis; Topotecan; Treatment Outcome

1997
Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Seminars in oncology, 1997, Volume: 24, Issue:5 Suppl 15

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Confidence Intervals; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Humans; Incidence; Infusions, Intravenous; Laparotomy; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Reoperation; Spain; Survival Rate; Thrombocytopenia; Treatment Outcome

1997
Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Seminars in oncology, 1997, Volume: 24, Issue:5 Suppl 15

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cause of Death; Cisplatin; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Greece; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Remission Induction; Survival Rate; Thrombocytopenia

1997
Salvage weekly paclitaxel in recurrent ovarian cancer.
    Seminars in oncology, 1997, Volume: 24, Issue:5 Suppl 15

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; CA-125 Antigen; Cohort Studies; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fever; Follow-Up Studies; Hospitalization; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Remission Induction; Retrospective Studies; Salvage Therapy; Tomography, X-Ray Computed

1997
Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1996, Volume: 2, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Survival Rate; Taxoids

1996
Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-01, Volume: 19, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cross-Over Studies; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Europe; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Survival Rate; Topotecan; United States

2001

Other Studies

212 other study(ies) available for paclitaxel and Epithelial Neoplasms

ArticleYear
The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.
    Gynecologic oncology, 2023, Volume: 173

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Treatment Outcome

2023
Reporting 'Denominator' data is essential for benchmarking and quality standards in ovarian cancer.
    Gynecologic oncology, 2017, Volume: 146, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benchmarking; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cohort Studies; Female; Guideline Adherence; Gynecologic Surgical Procedures; Gynecology; Humans; Medical Oncology; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Surgical Oncology; Survival Analysis; Treatment Outcome

2017
Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study.
    Gynecologic oncology, 2017, Volume: 146, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Catheters, Indwelling; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Randomized Controlled Trials as Topic; Tumor Microenvironment

2017
Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer.
    Journal of gynecologic oncology, 2017, Volume: 28, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Carboplatin; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Practice Guidelines as Topic; Retrospective Studies; Survival Rate

2017
Subtypes of stage IV ovarian cancer; response to treatment and patterns of disease recurrence.
    Gynecologic oncology, 2017, Volume: 146, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; New Zealand; Ovarian Neoplasms; Paclitaxel; Pleural Effusion, Malignant; Prognosis; Retrospective Studies; Treatment Outcome

2017
Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women.
    Gynecologic oncology, 2017, Volume: 146, Issue:2

    Topics: Adenocarcinoma, Clear Cell; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Infusions, Parenteral; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome

2017
Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers.
    British journal of cancer, 2017, Aug-08, Volume: 117, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease Progression; Drug Resistance, Neoplasm; Epithelium; Female; Forkhead Box Protein O1; Forkhead Box Protein O3; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Protein Array Analysis; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Young Adult

2017
Is macrocytosis a potential biomarker of the efficacy of dose-dense paclitaxel-carboplatin combination therapy in patients with epithelial ovarian cancer?
    Anti-cancer drugs, 2017, Volume: 28, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Erythrocytes, Abnormal; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies

2017
Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2017, Volume: 27, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Female; Forkhead Box Protein M1; Humans; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Signal Transduction; Thiostrepton

2017
WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response.
    Cell death & disease, 2017, 07-27, Volume: 8, Issue:7

    Topics: Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Female; Gene Expression Regulation, Neoplastic; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; RNA, Small Interfering; Tumor Suppressor Proteins; WW Domain-Containing Oxidoreductase

2017
Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snail‑glycolysis pathways.
    Oncology reports, 2017, Volume: 38, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glucosides; Glycolysis; Herbal Medicine; Humans; Hyaluronan Receptors; Hydrolyzable Tannins; Neoplasm Proteins; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proteomics; Signal Transduction; STAT3 Transcription Factor

2017
In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer.
    Proceedings of the National Academy of Sciences of the United States of America, 2017, 08-29, Volume: 114, Issue:35

    Topics: Apoptosis; beta Karyopherins; Carcinoma, Ovarian Epithelial; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Neoplastic; Humans; Ivermectin; Loss of Function Mutation; Neoplasms, Glandular and Epithelial; Oncogenes; Ovarian Neoplasms; Paclitaxel; RNA, Small Interfering

2017
iCTC drug resistance (CDR) Testing ex vivo for evaluation of available therapies to treat patients with epithelial ovarian cancer.
    Gynecologic oncology, 2017, Volume: 147, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Neoplastic Cells, Circulating; Ovarian Neoplasms; Paclitaxel

2017
The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2017, Volume: 27, Issue:9

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Doxorubicin; Drug Costs; European Union; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Randomized Controlled Trials as Topic; Survival Rate; Tetrahydroisoquinolines; Trabectedin

2017
The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2017, Volume: 27, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies

2017
Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429.
    Cell death & disease, 2018, 01-11, Volume: 8, Issue:1

    Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cell Hypoxia; Cell Line, Tumor; CSK Tyrosine-Protein Kinase; Drug Resistance, Neoplasm; Drug Synergism; Female; Flavonoids; G2 Phase Cell Cycle Checkpoints; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; M Phase Cell Cycle Checkpoints; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor; Xenograft Model Antitumor Assays

2018
Efficacy of weekly administration of paclitaxel and carboplatin for advanced ovarian cancer patients with poor performance status.
    International journal of clinical oncology, 2018, Volume: 23, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate

2018
Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
    Pharmacological reports : PR, 2018, Volume: 70, Issue:3

    Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Metformin; Neoplasms, Glandular and Epithelial; NF-kappa B; Ovarian Neoplasms; Paclitaxel; Signal Transduction; Survival Rate

2018
Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
    The journal of obstetrics and gynaecology research, 2018, Volume: 44, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Outcome Assessment, Health Care; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Young Adult

2018
Retrospective analysis of the survival benefit of chemotherapy for recurrent or advanced epithelial ovarian carcinoma in patients previously treated with paclitaxel plus platinum-based chemotherapy.
    European journal of gynaecological oncology, 2016, Volume: 37, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Humans; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies

2016
Role and timing of second-line therapies for patients with recurrent platinum-resistant ovarian epithelial cancer.
    European journal of gynaecological oncology, 2017, Volume: 38, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Retreatment; Retrospective Studies; Survival Rate; Topotecan

2017
Upregulation of miR-874-3p and miR-874-5p inhibits epithelial ovarian cancer malignancy via SIK2.
    Journal of biochemical and molecular toxicology, 2018, Volume: 32, Issue:8

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; MicroRNAs; Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Protein Binding; Protein Serine-Threonine Kinases; Transfection; Up-Regulation

2018
Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer.
    Cancer immunology, immunotherapy : CII, 2018, Volume: 67, Issue:11

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; B7-H1 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Cycle Checkpoints; Drug Combinations; Drug Synergism; Female; Humans; Immunotherapy; Mice; Mice, SCID; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured

2018
SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth.
    Gynecologic oncology, 2018, Volume: 151, Issue:2

    Topics: Animals; Apoptosis; Axl Receptor Tyrosine Kinase; Carcinoma, Ovarian Epithelial; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; RNA, Neoplasm; Tubulin Modulators; Xenograft Model Antitumor Assays

2018
Impact of Adding Bevacizumab to Paclitaxel + Carboplatin for Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: A Propensity Score Matching Analysis.
    The Tokai journal of experimental and clinical medicine, 2018, Sep-20, Volume: 43, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Propensity Score; Retrospective Studies; Time Factors; Treatment Outcome

2018
Safety and efficacy of neoadjuvant chemotherapy containing bevacizumab and interval debulking surgery for advanced epithelial ovarian cancer: A feasibility study.
    Journal of surgical oncology, 2018, Volume: 118, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Cytoreduction Surgical Procedures; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Prospective Studies; Safety

2018
Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer--a population-based study.
    Gynecologic oncology, 2013, Volume: 129, Issue:2

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Australia; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Female; Guideline Adherence; Humans; Logistic Models; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Practice Guidelines as Topic; Practice Patterns, Physicians'; Registries

2013
The MAD1 1673 G → A polymorphism alters the function of the mitotic spindle assembly checkpoint and is associated with a worse response to induction chemotherapy and sensitivity to treatment in patients with advanced epithelial ovarian cancer.
    Pharmacogenetics and genomics, 2013, Volume: 23, Issue:4

    Topics: Biomarkers, Pharmacological; Calcium-Binding Proteins; Carcinoma, Ovarian Epithelial; Cell Cycle Proteins; Chromosomal Instability; Female; Genetic Association Studies; Humans; M Phase Cell Cycle Checkpoints; Mad2 Proteins; Microtubules; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Nocodazole; Nuclear Proteins; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide; Repressor Proteins

2013
Progression-free survival is accurately predicted in patients treated with chemotherapy for epithelial ovarian cancer by the histoculture drug response assay in a prospective correlative clinical trial at a single institution.
    Anticancer research, 2013, Volume: 33, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials as Topic; Disease-Free Survival; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Tumor Cells, Cultured

2013
Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers.
    American journal of obstetrics and gynecology, 2013, Volume: 208, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Drug Administration Schedule; Drug Tolerance; Fallopian Tube Neoplasms; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome

2013
Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Netherlands; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Survival; Treatment Outcome

2013
Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.
    Gynecologic oncology, 2013, Volume: 130, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cyclophosphamide; Disease-Free Survival; Female; Humans; Infusions, Parenteral; Lymphatic Metastasis; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate

2013
Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
    American journal of obstetrics and gynecology, 2013, Volume: 209, Issue:1

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Epothilones; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Microtubules; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Real-Time Polymerase Chain Reaction; Taxoids; Tubulin; Tubulin Modulators

2013
DNA repair gene associated with clinical outcome of epithelial ovarian cancer treated with platinum-based chemotherapy.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Disease-Free Survival; DNA Repair; DNA-Binding Proteins; Female; Genotype; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Survival; Treatment Outcome; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein

2013
Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy.
    Journal of experimental & clinical cancer research : CR, 2013, Apr-30, Volume: 32

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Female; Gene Expression; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Prognosis; tau Proteins; Treatment Outcome

2013
A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis.
    Proceedings of the National Academy of Sciences of the United States of America, 2013, Jun-11, Volume: 110, Issue:24

    Topics: Antineoplastic Agents; Blotting, Western; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Coculture Techniques; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; MicroRNAs; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Vascular Endothelial Growth Factor B; Vascular Endothelial Growth Factor Receptor-2

2013
Weekly carboplatin with paclitaxel compared to standard three-weekly treatment in advanced epithelial ovarian carcinoma--a retrospective study.
    Gynecologic oncology, 2014, Volume: 132, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Survival Rate

2014
Platelet-derived growth factor receptor beta serum concentrations during first-line therapy in ovarian cancer.
    Oncology, 2013, Volume: 85, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Receptor, Platelet-Derived Growth Factor beta; Treatment Outcome; Vascular Endothelial Growth Factor A

2013
The overexpression of P21-activated kinase 5 (PAK5) promotes paclitaxel-chemoresistance of epithelial ovarian cancer.
    Molecular and cellular biochemistry, 2013, Volume: 383, Issue:1-2

    Topics: Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; p21-Activated Kinases; Paclitaxel; RNA Interference

2013
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas.
    Gynecologic oncology, 2013, Volume: 131, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Carcinoma, Ovarian Epithelial; Disease Progression; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Pharmacogenetics; Polymorphism, Single Nucleotide; Proportional Hazards Models

2013
The role of surgery in the management of patients with platinum-sensitive recurrent ovarian cancer: survey among Dutch gynecologists and medical oncologists.
    Gynecologic oncology, 2013, Volume: 131, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Attitude of Health Personnel; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Data Collection; Female; Gynecology; Humans; Medical Oncology; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Netherlands; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Surveys and Questionnaires

2013
Preoperative 18F-FDG PET/CT in the management of advanced epithelial ovarian cancer.
    Gynecologic oncology, 2013, Volume: 131, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome

2013
Perioperative and clinical outcomes in the management of epithelial ovarian cancer using a robotic or abdominal approach.
    Gynecologic oncology, 2013, Volume: 131, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Female; Gynecologic Surgical Procedures; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Robotics; Treatment Outcome

2013
[Chemotherapy in epithelial ovarian cancer].
    Gynecologie, obstetrique & fertilite, 2013, Volume: 41, Issue:10

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Treatment Outcome

2013
Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
    Gynecologic oncology, 2013, Volume: 131, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Treatment Outcome

2013
Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer.
    British journal of cancer, 2014, Jan-07, Volume: 110, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Interleukin-6; Janus Kinase 2; Neoplasm Grading; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Receptors, Colony-Stimulating Factor; Signal Transduction; STAT3 Transcription Factor

2014
Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer.
    British journal of cancer, 2014, Jan-21, Volume: 110, Issue:2

    Topics: Carcinoma, Ovarian Epithelial; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Choline; Choline Kinase; Down-Regulation; Doxorubicin; Female; Humans; Lipid Metabolism; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phosphorylcholine; Platinum; RNA Interference; Signal Transduction; Transcriptome

2014
Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness.
    Gynecologic oncology, 2014, Volume: 132, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis

2014
Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment.
    Cancer medicine, 2013, Volume: 2, Issue:6

    Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; HEK293 Cells; Humans; Hyaluronan Receptors; Mice; Mice, Nude; Myeloid Differentiation Factor 88; Neoplasms, Glandular and Epithelial; Neoplastic Stem Cells; Ovarian Neoplasms; Paclitaxel; Phenotype; Recurrence; Snail Family Transcription Factors; Transcription Factors; Tumor Burden; Xenograft Model Antitumor Assays

2013
The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study.
    Gynecologic oncology, 2014, Volume: 132, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cohort Studies; Disease-Free Survival; Female; Humans; Leukocytosis; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Preoperative Period; Proportional Hazards Models; Retrospective Studies; Young Adult

2014
Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway.
    Scientific reports, 2014, Jan-23, Volume: 4

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma, Ovarian Epithelial; Cell Proliferation; Cholinergic Antagonists; Drug Resistance, Neoplasm; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Female; Humans; Interleukin-6; Lactones; Lymphocyte Antigen 96; Molecular Docking Simulation; Myeloid Differentiation Factor 88; Neoplasms, Glandular and Epithelial; NF-kappa B; Ovarian Neoplasms; Paclitaxel; Protein Conformation; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sesquiterpenes; Signal Transduction; Toll-Like Receptor 4; Tumor Cells, Cultured

2014
Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer.
    Gynecologic oncology, 2014, Volume: 132, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biosimilar Pharmaceuticals; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials as Topic; Cohort Studies; Cost-Benefit Analysis; Female; Humans; Markov Chains; Middle Aged; Models, Economic; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel

2014
Security and efficiency of a closed-system, turbulent-flow circuit for hyperthermic intraperitoneal chemotherapy after cytoreductive ovarian surgery: perioperative outputs.
    Archives of gynecology and obstetrics, 2014, Volume: 290, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome

2014
A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
    American journal of obstetrics and gynecology, 2014, Volume: 211, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prospective Studies; ROC Curve; Survival Analysis; Treatment Outcome

2014
Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression.
    International journal of oncology, 2014, Volume: 44, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; tau Proteins; Treatment Outcome

2014
In vitro chemosensitivity assay of ascites in epithelial ovarian cancer.
    European journal of gynaecological oncology, 2013, Volume: 34, Issue:6

    Topics: Antineoplastic Agents; Ascites; Carboplatin; Carcinoma, Ovarian Epithelial; Coloring Agents; Deoxycytidine; Disease Progression; Drug Screening Assays, Antitumor; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Survival Rate; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2013
Beclin 1 expression in ovarian tissues and its effects on ovarian cancer prognosis.
    International journal of molecular sciences, 2014, Mar-26, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Aged; Apoptosis Regulatory Proteins; Beclin-1; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Membrane Proteins; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Paclitaxel; Prognosis; Young Adult

2014
Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer.
    Gynecologic oncology, 2014, Volume: 133, Issue:1

    Topics: Adiposity; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Body Mass Index; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Intra-Abdominal Fat; Middle Aged; Multivariate Analysis; Neoplasms, Glandular and Epithelial; Obesity; Ovarian Neoplasms; Overweight; Paclitaxel; Pilot Projects; Prognosis; Proportional Hazards Models; Retrospective Studies; Subcutaneous Fat; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor A

2014
Bevacizumab in treatment of high-risk ovarian cancer--a cost-effectiveness analysis.
    The oncologist, 2014, Volume: 19, Issue:5

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cost-Benefit Analysis; Disease-Free Survival; Female; Health Care Costs; Humans; Middle Aged; Models, Economic; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Vascular Endothelial Growth Factor A

2014
Effect of gonadotropin-releasing hormone agonist on ES-2 ovarian cancer cells.
    Taiwanese journal of obstetrics & gynecology, 2014, Volume: 53, Issue:1

    Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Cytotoxins; Dose-Response Relationship, Drug; Drug Synergism; Female; Gonadotropin-Releasing Hormone; Humans; Neoplasm Invasiveness; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Receptors, LHRH

2014
Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer.
    American journal of obstetrics and gynecology, 2014, Volume: 211, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Ovarian Epithelial; Cohort Studies; Cytoreduction Surgical Procedures; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prognosis; Remission Induction; Retrospective Studies; Treatment Outcome; Tumor Burden

2014
The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genotype; Humans; Immunohistochemistry; MicroRNAs; Middle Aged; Myeloid Differentiation Factor 88; Neoplasms, Glandular and Epithelial; Neoplastic Stem Cells; Ovarian Neoplasms; Paclitaxel; Phenotype; Prognosis; RNA, Small Interfering; Signal Transduction; Survival Analysis; Toll-Like Receptor 4

2014
Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer.
    Journal of gynecologic oncology, 2014, Volume: 25, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Adhesion Molecules; Epithelial Cell Adhesion Molecule; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Prognosis; Tissue Banks; Treatment Outcome

2014
Sequential combination of flavopiridol with Taxol synergistically suppresses human ovarian carcinoma growth.
    Archives of gynecology and obstetrics, 2015, Volume: 291, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Synergism; Female; Flavonoids; Humans; In Situ Nick-End Labeling; Mice; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Piperidines; Xenograft Model Antitumor Assays

2015
The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1α and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways.
    Oncotarget, 2014, Aug-15, Volume: 5, Issue:15

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Movement; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Inbred BALB C; Mice, Nude; Multiprotein Complexes; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phosphoprotein Phosphatases; Phosphoproteins; Phosphorylation; Ribosomal Protein S6 Kinases; Signal Transduction; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2014
IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells.
    Cancer letters, 2014, Nov-28, Volume: 354, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Molecular Targeted Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Podophyllotoxin; Proteasome Endopeptidase Complex; Receptor, IGF Type 1

2014
Inhibition of epithelial ovarian cancer by Minnelide, a water-soluble pro-drug.
    Gynecologic oncology, 2014, Volume: 135, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diterpenes; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Electric Impedance; Epoxy Compounds; Female; Humans; Mice; Mice, Nude; Neoplasms, Glandular and Epithelial; Organophosphates; Ovarian Neoplasms; Paclitaxel; Phenanthrenes; Prodrugs; Xenograft Model Antitumor Assays

2014
Variation and prognostic value of serum plasminogen activator inhibitor-1 before and after chemotherapy in patients with epithelial ovarian cancer.
    The journal of obstetrics and gynaecology research, 2014, Volume: 40, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; China; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Plasminogen Activator Inhibitor 1; Prognosis; Retrospective Studies; Survival Analysis

2014
The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction.
    Annals of surgical oncology, 2015, Volume: 22, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate

2015
Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.
    Gynecologic oncology, 2014, Volume: 135, Issue:2

    Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Carcinosarcoma; Cohort Studies; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Prognosis; Reoperation; Retrospective Studies; Treatment Outcome; Young Adult

2014
ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.
    Yonsei medical journal, 2014, Volume: 55, Issue:6

    Topics: Adenocarcinoma, Clear Cell; Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Ifosfamide; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Predictive Value of Tests; Sensitivity and Specificity; Taxoids

2014
Establishment of a New Ovarian Cancer Cell Line CA5171.
    Reproductive sciences (Thousand Oaks, Calif.), 2015, Volume: 22, Issue:6

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Shape; Cisplatin; Class I Phosphatidylinositol 3-Kinases; DNA Copy Number Variations; Doxorubicin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Humans; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phenotype; Phosphatidylinositol 3-Kinases; Polymorphism, Single Nucleotide; PTEN Phosphohydrolase; Tumor Suppressor Protein p53

2015
Feasibility and safety of a modified outpatient regimen with intravenous/intraperitoneal chemotherapy for optimally debulked stage III ovarian cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2015, Volume: 25, Issue:2

    Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Feasibility Studies; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Treatment Outcome

2015
Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma.
    Gynecologic oncology, 2015, Volume: 136, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Humans; Hyaluronan Receptors; Interleukin-6; Interleukin-8; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel

2015
Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer.
    British journal of cancer, 2015, Jan-20, Volume: 112, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Cisplatin; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Peritoneum

2015
Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer.
    American journal of obstetrics and gynecology, 2015, Volume: 212, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Genes, BRCA1; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Prognosis; Proportional Hazards Models

2015
Addition of epirubicin to conventional chemotherapy in patients with advanced ovarian cancer: sequential therapy -a retrospective evaluation. .
    Turkish journal of medical sciences, 2014, Volume: 44, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Young Adult

2014
FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Oncotarget, 2015, Feb-10, Volume: 6, Issue:4

    Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Humans; Immunohistochemistry; Mice, Inbred NOD; Mice, SCID; Neoplasms, Glandular and Epithelial; Neoplastic Stem Cells; Ovarian Neoplasms; Paclitaxel; RNA Interference; Survival Analysis; Thiostrepton; Tumor Burden; Xenograft Model Antitumor Assays

2015
Survival outcomes of recurrent epithelial ovarian cancer: experience from a Thailand northern tertiary care center.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:24

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Survival Rate; Tertiary Care Centers

2014
Three-dimensional collagen type I matrix up-regulates nuclear isoforms of the microtubule associated protein tau implicated in resistance to paclitaxel therapy in ovarian carcinoma.
    International journal of molecular sciences, 2015, Feb-04, Volume: 16, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Cell Culture Techniques; Collagen Type I; Drug Resistance, Neoplasm; Female; Gene Silencing; Humans; Immunohistochemistry; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Protein Isoforms; RNA Interference; RNA, Small Interfering; tau Proteins

2015
Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
    The international journal of biochemistry & cell biology, 2015, Volume: 61

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Differentiation; Cell Line, Tumor; Cell Survival; Cisplatin; Female; Humans; Mice; Myeloid Differentiation Factor 88; Neoplasms, Glandular and Epithelial; NF-kappa B; Ovarian Neoplasms; Paclitaxel; Signal Transduction; Transfection; Xenograft Model Antitumor Assays

2015
Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, May-01, Volume: 33, Issue:13

    Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chi-Square Distribution; Cisplatin; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasms, Glandular and Epithelial; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome

2015
Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer.
    Oncotarget, 2015, Apr-20, Volume: 6, Issue:11

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, Transgenic; Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Recurrence; Up-Regulation; Xenograft Model Antitumor Assays

2015
Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Jul-01, Volume: 21, Issue:13

    Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Adhesion Molecules; Cell Line, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fibroblasts; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Transcriptome; Treatment Outcome; Tumor Microenvironment; Up-Regulation

2015
Primary peritoneal cancer: study of 14 cases and comparison with epithelial ovarian cancer.
    European journal of gynaecological oncology, 2015, Volume: 36, Issue:1

    Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Survival Rate

2015
Involvement of GRP78 in the Resistance of Ovarian Carcinoma Cells to Paclitaxel.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:8

    Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Female; Gene Knockdown Techniques; Heat-Shock Proteins; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Real-Time Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering

2015
TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas.
    Gynecologic oncology, 2015, Volume: 138, Issue:1

    Topics: Carcinoma, Ovarian Epithelial; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Epothilones; Female; Genes, p53; Humans; Middle Aged; Mutation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Tubulin Modulators; Tumor Suppressor Protein p53

2015
Impact of obesity on secondary cytoreductive surgery and overall survival in women with recurrent ovarian cancer.
    Gynecologic oncology, 2015, Volume: 138, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Obesity; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate

2015
A non-randomized confirmatory study regarding selection of fertility-sparing surgery for patients with epithelial ovarian cancer: Japan Clinical Oncology Group Study (JCOG1203).
    Japanese journal of clinical oncology, 2015, Volume: 45, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Female; Fertility; Humans; Infertility, Female; Japan; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Salpingostomy; Treatment Outcome

2015
Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer - a population-based study.
    Acta oncologica (Stockholm, Sweden), 2016, Volume: 55, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cohort Studies; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Time Factors

2016
COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilization.
    Oncotarget, 2015, Sep-15, Volume: 6, Issue:27

    Topics: Antineoplastic Agents; Binding Sites; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; CCAAT-Enhancer-Binding Protein-beta; Cell Line, Tumor; Cisplatin; Collagen Type XI; Drug Resistance, Neoplasm; Enzyme Activation; Female; Gene Expression Profiling; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; RNA Interference; RNA, Messenger; RNA, Small Interfering; Ubiquitination

2015
Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma.
    BMC cancer, 2015, Jul-08, Volume: 15

    Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cyclin G1; DNA Methylation; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genetic Loci; Humans; Methylation; MicroRNAs; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; RNA Interference; RNA, Messenger

2015
Toxicity of intraperitoneal chemotherapy and risk factors for severe toxicity in optimally debulked ovarian cancer patients.
    Taiwanese journal of obstetrics & gynecology, 2015, Volume: 54, Issue:3

    Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Catheter Obstruction; Catheters, Indwelling; Chemotherapy-Induced Febrile Neutropenia; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Diarrhea; Disease-Free Survival; Female; Humans; Ileus; Infusions, Parenteral; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Risk Factors; Survival Rate; Vomiting; Withholding Treatment

2015
Centralisation of epithelial ovarian cancer surgery: results on survival from a peripheral teaching hospital.
    European journal of obstetrics, gynecology, and reproductive biology, 2015, Volume: 192

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cyclophosphamide; Cytoreduction Surgical Procedures; Delivery of Health Care; Disease-Free Survival; Female; Follow-Up Studies; Health Status; Hospitals, Teaching; Humans; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Netherlands; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate

2015
Genetic variation of CYP3A5 influences paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients.
    Journal of clinical pharmacology, 2016, Volume: 56, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Bone Marrow; Carboplatin; Carcinoma, Ovarian Epithelial; Cytochrome P-450 CYP3A; Female; Genotype; Humans; Leukocyte Count; Leukopenia; Middle Aged; Neoplasms, Glandular and Epithelial; Neutrophils; Ovarian Neoplasms; Paclitaxel; Paresthesia; Pharmacogenomic Variants; Prospective Studies

2016
Ovarian Cancer Survival and Chemotherapy Dosing, Body Mass Index, and Body Surface Area : Are We There Yet?
    JAMA oncology, 2015, Volume: 1, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Cisplatin; Drug Dosage Calculations; Humans; Neoplasms, Glandular and Epithelial; Obesity; Ovarian Neoplasms; Paclitaxel

2015
Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.
    JAMA oncology, 2015, Volume: 1, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; California; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Drug Dosage Calculations; Health Maintenance Organizations; Humans; Logistic Models; Middle Aged; Multivariate Analysis; Neoplasms, Glandular and Epithelial; Obesity; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Registries; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Young Adult

2015
Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
    Archives of gynecology and obstetrics, 2016, Volume: 293, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; China; Cisplatin; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Treatment Outcome

2016
Metformin and epithelial ovarian cancer therapeutics.
    Cellular oncology (Dordrecht), 2015, Volume: 38, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Blotting, Western; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Metformin; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured

2015
Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).
    Gynecologic oncology, 2015, Volume: 139, Issue:2

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cohort Studies; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Severity of Illness Index; Survival Rate; Treatment Outcome

2015
Down-regulated expression of miR-134 contributes to paclitaxel resistance in human ovarian cancer cells.
    FEBS letters, 2015, Oct-07, Volume: 589, Issue:20 Pt B

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Base Sequence; Blotting, Western; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; p21-Activated Kinases; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sequence Homology, Nucleic Acid

2015
Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma.
    Oncotarget, 2015, Oct-27, Volume: 6, Issue:33

    Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Female; Gene Knockdown Techniques; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Kaplan-Meier Estimate; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Glandular and Epithelial; Omeprazole; Ovarian Neoplasms; Paclitaxel; Proton Pump Inhibitors; RNA, Small Interfering; Transfection; Vacuolar Proton-Translocating ATPases; Xenograft Model Antitumor Assays

2015
Restoration of paclitaxel resistance by CDK1 intervention in drug-resistant ovarian cancer.
    Carcinogenesis, 2015, Volume: 36, Issue:12

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzazepines; Carcinoma, Ovarian Epithelial; CDC2 Protein Kinase; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Female; Humans; Indoles; Mice, Inbred C57BL; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Xenograft Model Antitumor Assays

2015
Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma.
    Oncotarget, 2015, Nov-24, Volume: 6, Issue:37

    Topics: Adipokines; Adult; Aged; Analysis of Variance; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Chitinase-3-Like Protein 1; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lectins; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms, Glandular and Epithelial; Outcome Assessment, Health Care; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference

2015
A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
    Gynecologic oncology, 2016, Volume: 140, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Retrospective Studies; Young Adult

2016
Anti-proliferative activity and cell cycle arrest induced by evodiamine on paclitaxel-sensitive and -resistant human ovarian cancer cells.
    Scientific reports, 2015, Nov-10, Volume: 5

    Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Mice; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quinazolines

2015
miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis.
    Oncology reports, 2016, Volume: 35, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Signal Transduction; X-Linked Inhibitor of Apoptosis Protein

2016
Loss of ITM2A, a novel tumor suppressor of ovarian cancer through G2/M cell cycle arrest, is a poor prognostic factor of epithelial ovarian cancer.
    Gynecologic oncology, 2016, Volume: 140, Issue:3

    Topics: Adenoma; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cytoreduction Surgical Procedures; Drug Resistance, Neoplasm; Female; G2 Phase Cell Cycle Checkpoints; Humans; Inhibitory Concentration 50; M Phase Cell Cycle Checkpoints; Membrane Proteins; Mice; Mice, Inbred BALB C; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Paclitaxel; Tumor Stem Cell Assay

2016
Singapore Cancer Network (SCAN) Guidelines for Front-Line Systemic Therapy of Newly Diagnosed Advanced Epithelial Ovarian Cancer.
    Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:10

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Parenteral; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Polyethylene Glycols; Singapore

2015
Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma.
    Molecular cancer therapeutics, 2016, Volume: 15, Issue:4

    Topics: Acyclic Monoterpenes; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Membrane Potential, Mitochondrial; Mice; Monoterpenes; Nanoparticles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Reactive Oxygen Species; Tumor Burden; Xenograft Model Antitumor Assays

2016
SMIFH2-mediated mDia formin functional inhibition potentiates chemotherapeutic targeting of human ovarian cancer spheroids.
    Biochemical and biophysical research communications, 2016, Mar-25, Volume: 472, Issue:1

    Topics: Actins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Carrier Proteins; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Female; Formins; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Spheroids, Cellular; Thiones; Uracil

2016
Clinical Practice of Adjuvant Chemotherapy in Patients with Early-Stage Epithelial Ovarian Cancer.
    Chemotherapy, 2016, Volume: 61, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models

2016
Prognostic role of excision repair cross complementing-1 and topoisomerase-1 expression in epithelial ovarian cancer.
    Taiwanese journal of obstetrics & gynecology, 2016, Volume: 55, Issue:2

    Topics: Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cyclophosphamide; Cytoreduction Surgical Procedures; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Proto-Oncogene Proteins c-myc; Survival Rate; tau Proteins; Tumor Suppressor Protein p53

2016
Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
    Gynecologic oncology, 2016, Volume: 142, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome

2016
Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study.
    Chinese journal of cancer, 2016, May-09, Volume: 35

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Injections, Intraperitoneal; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Propensity Score; Prospective Studies; Treatment Outcome

2016
Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
    Oncotarget, 2016, Jul-26, Volume: 7, Issue:30

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; DNA Copy Number Variations; Female; Follow-Up Studies; High-Throughput Nucleotide Sequencing; Homologous Recombination; Humans; Kaplan-Meier Estimate; Middle Aged; Mutation; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Sequence Analysis, DNA; Treatment Outcome; Tumor Suppressor Protein p53

2016
Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study.
    Gynecologic oncology, 2016, Volume: 142, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Case-Control Studies; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel

2016
Possible surrogate marker for an effective dose-dense chemotherapy in treating ovarian cancer.
    Taiwanese journal of obstetrics & gynecology, 2016, Volume: 55, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Female; Humans; Lymphocyte Count; Membrane Proteins; Middle Aged; Monocytes; Neoplasms, Glandular and Epithelial; Neutrophils; Ovarian Neoplasms; Paclitaxel; Platelet Count; Retrospective Studies; Treatment Outcome

2016
Racial/Ethnic Disparities in Ovarian Cancer Treatment and Survival.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Dec-01, Volume: 22, Issue:23

    Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cohort Studies; Ethnicity; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Racial Groups; Young Adult

2016
Hyperthermic intraperitoneal chemotherapy with paclitaxel or cisplatin in patients with stage III-C/IV ovarian cancer. Is there any difference?
    Surgical oncology, 2016, Volume: 25, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate

2016
The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study.
    Journal of cancer research and clinical oncology, 2016, Volume: 142, Issue:11

    Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Taxoids

2016
Inhibition of pregnane X receptor pathway contributes to the cell growth inhibition and apoptosis of anticancer agents in ovarian cancer cells.
    International journal of oncology, 2016, Volume: 49, Issue:3

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Female; Humans; Ketoconazole; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phthalic Acids; Pregnane X Receptor; Pregnenolone; Receptors, Steroid; RNA, Small Interfering; Signal Transduction

2016
Paraaortic node recurrence 25 years after removal of epithelial ovarian carcinoma.
    The journal of obstetrics and gynaecology research, 2016, Volume: 42, Issue:11

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Lymphoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Remission Induction; Treatment Outcome

2016
Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.
    Gynecologic oncology, 2016, Volume: 143, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies

2016
NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
    Oncotarget, 2016, Nov-01, Volume: 7, Issue:44

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carcinogenesis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Chemokines; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorescent Antibody Technique; Growth Differentiation Factor 15; Humans; Immunohistochemistry; Inflammation; Kaplan-Meier Estimate; MAP Kinase Kinase Kinases; Microscopy, Confocal; Myeloid Differentiation Factor 88; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Neoplastic Stem Cells; NF-kappa B; Ovarian Neoplasms; Ovary; Paclitaxel; Prognosis; Signal Transduction; Smad4 Protein; Sulindac; Up-Regulation

2016
Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.
    Gynecologic oncology, 2016, Volume: 143, Issue:3

    Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Agents; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Time Factors

2016
Minimally invasive versus standard laparotomic interval debulking surgery in ovarian neoplasm: A single-institution retrospective case-control study.
    Gynecologic oncology, 2016, Volume: 143, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Case-Control Studies; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Laparoscopy; Laparotomy; Middle Aged; Minimally Invasive Surgical Procedures; Neoadjuvant Therapy; Neoplasm Grading; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Retrospective Studies

2016
The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials.
    Gynecologic oncology, 2016, Volume: 143, Issue:3

    Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Cytoreduction Surgical Procedures; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Survival Rate; Time Factors

2016
Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review.
    Gynecologic oncology, 2017, Volume: 144, Issue:1

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Comorbidity; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate

2017
Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancer.
    Gynecologic oncology, 2017, Volume: 144, Issue:1

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Germany; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Postoperative Complications; Retrospective Studies; Severity of Illness Index; Survival Rate; Young Adult

2017
Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies.
    Cancer research and treatment, 2017, Volume: 49, Issue:4

    Topics: Adult; Animals; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carboplatin; Carcinoma, Ovarian Epithelial; Disease Models, Animal; Drug Evaluation, Preclinical; ErbB Receptors; Female; Genomic Instability; Heterografts; Humans; Mice; Middle Aged; Molecular Targeted Therapy; Neoplasm Grading; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Translational Research, Biomedical; Xenograft Model Antitumor Assays

2017
Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial.
    Gynecologic oncology, 2017, Volume: 145, Issue:1

    Topics: Administration, Intravenous; Anemia; Antineoplastic Agents; Blood Transfusion; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Decision Support Techniques; Disease-Free Survival; Drug Costs; Female; Filgrastim; Hematologic Agents; Hospitalization; Humans; Markov Chains; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Proportional Hazards Models; Randomized Controlled Trials as Topic

2017
Yin yang 1 modulates taxane response in epithelial ovarian cancer.
    Molecular cancer research : MCR, 2009, Volume: 7, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Binding Sites; Cell Movement; Cell Proliferation; Cisplatin; Comparative Genomic Hybridization; Docetaxel; E2F Transcription Factors; Epigenesis, Genetic; Female; Gene Expression Profiling; Humans; Immunoenzyme Techniques; Neoplasms, Glandular and Epithelial; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Survival Rate; Taxoids; Wound Healing; YY1 Transcription Factor

2009
The expression of dipeptidyl peptidase IV (DPPIV/CD26) is associated with enhanced chemosensitivity to paclitaxel in epithelial ovarian carcinoma cells.
    Cancer science, 2010, Volume: 101, Issue:2

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Mice; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel

2010
Glycoproteomics of paclitaxel resistance in human epithelial ovarian cancer cell lines: towards the identification of putative biomarkers.
    Journal of proteomics, 2010, Mar-10, Volume: 73, Issue:5

    Topics: Biomarkers; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Glycoproteins; HSP40 Heat-Shock Proteins; Humans; Membrane Glycoproteins; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proteomics; Thiolester Hydrolases; Triose-Phosphate Isomerase; Up-Regulation

2010
Neoadjuvant chemotherapy followed by interval cytoreductive surgery in patients with unresectable, advanced stage epithelial ovarian cancer: a single centre experience.
    Archives of gynecology and obstetrics, 2010, Volume: 282, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Survival Rate; Treatment Outcome

2010
Role of STAT3 decoy oligodeoxynucleotides on cell invasion and chemosensitivity in human epithelial ovarian cancer cells.
    Cancer genetics and cytogenetics, 2010, Volume: 197, Issue:1

    Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Basigin; Cell Line, Tumor; Electrophoretic Mobility Shift Assay; Female; Humans; Neoplasm Invasiveness; Neoplasms, Glandular and Epithelial; Oligodeoxyribonucleotides; Ovarian Neoplasms; Paclitaxel; STAT3 Transcription Factor; Transfection

2010
The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer.
    Neoplasia (New York, N.Y.), 2010, Volume: 12, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomimetics; Cell Line; Cisplatin; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Female; Immunoblotting; Mice; Mice, Inbred C57BL; Morbidity; Neoplasms, Glandular and Epithelial; Oligopeptides; Ovarian Neoplasms; Paclitaxel; Receptors, Vascular Endothelial Growth Factor; Survival Rate; Thrombospondin 1; Treatment Outcome; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2010
Characterisation of a multimeric protein complex associated with ERp57 within the nucleus in paclitaxel-sensitive and -resistant epithelial ovarian cancer cells: the involvement of specific conformational states of beta-actin.
    International journal of oncology, 2010, Volume: 37, Issue:2

    Topics: Actins; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Nucleus; Chromosome Segregation; Drug Resistance, Neoplasm; Female; Humans; Multiprotein Complexes; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Protein Binding; Protein Conformation; Protein Disulfide-Isomerases; Protein Multimerization; Structure-Activity Relationship

2010
Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
    Canadian journal of physiology and pharmacology, 2010, Volume: 88, Issue:6

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Female; Humans; Ki-67 Antigen; Mice; Mice, Nude; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Pyrrolidines; Xenograft Model Antitumor Assays

2010
Ovarian cancer care: it's time for "personalized" approaches.
    Oncology (Williston Park, N.Y.), 2010, Volume: 24, Issue:8

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; CA-125 Antigen; Carboplatin; Doxorubicin; Early Detection of Cancer; Female; Humans; Infusions, Parenteral; Membrane Proteins; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Patient Selection

2010
Challenges to the paclitaxel/carboplatin algorithm in ovarian cancer treatment.
    Oncology (Williston Park, N.Y.), 2010, Volume: 24, Issue:8

    Topics: Algorithms; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Female; Genes, BRCA1; Genes, BRCA2; Humans; Infusions, Intravenous; Infusions, Parenteral; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Patient Selection; Poly Adenosine Diphosphate Ribose; Proteins

2010
Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer.
    American journal of clinical oncology, 2011, Volume: 34, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Brachytherapy; Brain Neoplasms; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Combined Modality Therapy; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Taxoids; Treatment Outcome

2011
Role of gamma-synuclein in microtubule regulation.
    Experimental cell research, 2011, Jun-10, Volume: 317, Issue:10

    Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Cytoskeleton; Female; Fluorescent Antibody Technique; gamma-Synuclein; Humans; Microtubule-Associated Proteins; Microtubules; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Tubulin; Tumor Cells, Cultured

2011
C terminus of Clostridium perfringens enterotoxin downregulates CLDN4 and sensitizes ovarian cancer cells to Taxol and Carboplatin.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Mar-01, Volume: 17, Issue:5

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Carboplatin; Carcinoma, Ovarian Epithelial; Cells, Cultured; Claudin-4; Clostridium perfringens; Enterotoxins; Epithelial Cells; Female; Fluorescent Antibody Technique; Humans; In Situ Nick-End Labeling; Membrane Proteins; Mice; Mice, SCID; Neoplasms, Glandular and Epithelial; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Polymerase Chain Reaction; Proteasome Endopeptidase Complex; RNA, Messenger; Tight Junctions; Ubiquitin-Protein Ligase Complexes; Xenograft Model Antitumor Assays

2011
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-125 Antigen; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Cytotoxins; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome

2011
Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Loss, Surgical; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Disease-Free Survival; Female; Humans; Hysterectomy; Kaplan-Meier Estimate; Length of Stay; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Statistics, Nonparametric; Survival Analysis; Time Factors; Treatment Outcome; Young Adult

2011
Synergistic growth-inhibitory effects of fenretinide with either cisplatin or paclitaxel on human epithelial ovarian cancer cell line (SKOV-3).
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2004, Volume: 87 Suppl 3

    Topics: Anticarcinogenic Agents; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Growth Processes; Cisplatin; Drug Interactions; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fenretinide; Growth Inhibitors; Humans; Inhibitory Concentration 50; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured

2004
Overexpression of cofilin 1 can predict progression-free survival in patients with epithelial ovarian cancer receiving standard therapy.
    Human pathology, 2011, Volume: 42, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cofilin 1; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Laparotomy; Microdissection; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome

2011
Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.
    Gynecologic oncology, 2011, May-01, Volume: 121, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate

2011
Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Disease-Free Survival; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Topotecan

2011
Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?
    Gynecologic oncology, 2011, Jun-01, Volume: 121, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies

2011
Complementary and alternative medicine use among women receiving chemotherapy for ovarian cancer in 2 patient populations.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Carboplatin; Carcinoma, Ovarian Epithelial; Complementary Therapies; Cross-Sectional Studies; Female; Health Knowledge, Attitudes, Practice; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Surveys and Questionnaires; Survival Rate; Treatment Outcome; United Kingdom

2011
The changes in residual cancer burden after interval debulking surgery are effective in evaluating the response to adjuvant chemotherapy.
    Chemotherapy, 2011, Volume: 57, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies

2011
MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management.
    Gynecologic oncology, 2011, Volume: 122, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Female; Humans; MicroRNAs; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel

2011
Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer.
    Gynecologic oncology, 2011, Volume: 122, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Risk Factors; Taxoids; Young Adult

2011
Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer.
    Gynecologic oncology, 2011, Volume: 122, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Female; Humans; Markov Chains; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic

2011
Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: a single institution experience.
    Gynecologic oncology, 2011, Volume: 123, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis

2011
Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer.
    Annals of surgical oncology, 2012, Volume: 19, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Cohort Studies; Disease-Free Survival; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Proteins; Serum; WAP Four-Disulfide Core Domain Protein 2

2012
Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: report of two cases.
    Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Fatal Outcome; Female; Genes, BRCA1; Heterozygote; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Neoplasms, Glandular and Epithelial; Neoplasms, Second Primary; Ovarian Neoplasms; Paclitaxel; Platinum

2012
Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.
    Bulletin du cancer, 2011, Volume: 98, Issue:9

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Humans; Intestinal Fistula; Intestinal Perforation; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Rectovaginal Fistula; Retrospective Studies; Taxoids; Treatment Outcome; Urinary Bladder Fistula; Vascular Endothelial Growth Factor A; Vinblastine; Vinorelbine

2011
Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most useful prognostic factor.
    European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Male; Middle Aged; Models, Statistical; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Regression Analysis; Time Factors; Treatment Outcome

2012
Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
    The Journal of pathology, 2012, Volume: 226, Issue:5

    Topics: 3' Untranslated Regions; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Calcium-Binding Proteins; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Cycle Proteins; Cell Line, Tumor; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Mad2 Proteins; MicroRNAs; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Paraffin Embedding; Proportional Hazards Models; Repressor Proteins; Retrospective Studies; Risk Assessment; Risk Factors; RNA Interference; Time Factors; Transfection; Treatment Outcome

2012
Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2012, Volume: 22, Issue:2

    Topics: Adenocarcinoma, Papillary; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Pennsylvania; Registries; Retrospective Studies; Survival Analysis; Treatment Outcome

2012
Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2012, Volume: 80, Issue:2

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cations; Drug Delivery Systems; Female; Humans; KB Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms, Glandular and Epithelial; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Xenograft Model Antitumor Assays

2012
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
    Oncogene, 2012, Oct-18, Volume: 31, Issue:42

    Topics: 3' Untranslated Regions; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Protein; Carboplatin; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Genotype; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Mutation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; RNA Interference; Treatment Outcome

2012
Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.
    Gynecologic oncology, 2012, Volume: 125, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Combined Modality Therapy; Disease-Free Survival; DNA-Binding Proteins; DNA, Neoplasm; Endonucleases; Female; Genotype; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Paraffin Embedding; Polymorphism, Single Nucleotide; Predictive Value of Tests; Randomized Controlled Trials as Topic; Young Adult

2012
Prognostic value of biomarkers related to drug resistance in patients with advanced epithelial ovarian cancer.
    Anticancer research, 2012, Volume: 32, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Middle Aged; Multidrug Resistance-Associated Protein 2; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Survival Rate

2012
Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.
    Gynecologic oncology, 2012, Volume: 125, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Caspase 3; Cell Line, Tumor; Cisplatin; Elafin; Female; Fluorouracil; Gene Knockdown Techniques; Gene Silencing; Humans; Mice; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Transfection

2012
Secondary cytoreductive surgery outcomes of selected patients with paclitaxel/platinum sensitive recurrent epithelial ovarian cancer.
    Journal of surgical oncology, 2012, Sep-15, Volume: 106, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Treatment Outcome

2012
Evaluation of whether serum tumor markers in patients with epithelial ovarian carcinoma change following chemotherapy.
    Chinese medical journal, 2012, Volume: 125, Issue:3

    Topics: Aged; Biomarkers, Tumor; CA-125 Antigen; CA-19-9 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel

2012
Advances in epithelial ovarian cancer therapy.
    Current pharmaceutical design, 2012, Volume: 18, Issue:25

    Topics: Antineoplastic Agents; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel

2012
Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV).
    Journal of surgical oncology, 2013, Volume: 107, Issue:2

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cohort Studies; Drug Administration Schedule; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome

2013
Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models.
    British journal of cancer, 2012, Jul-10, Volume: 107, Issue:2

    Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Disease Progression; Female; Humans; Mice; Mice, Nude; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Vascular Endothelial Growth Factor A

2012
[The mRNA expression of BRCA1, ERCC1, TUBB3, PRR13 genes and their relationship with clinical chemosensitivity in primary epithelial ovarian cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Gene Expression Regulation, Neoplastic; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Repressor Proteins; RNA, Messenger; Tubulin

2012
Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera.
    Cancer investigation, 2012, Volume: 30, Issue:8

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Aptamers, Nucleotide; Artificial Gene Fusion; Base Sequence; Carcinoma, Ovarian Epithelial; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Molecular Sequence Data; Mucin-1; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Signal Transduction

2012
Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers.
    European journal of gynaecological oncology, 2012, Volume: 33, Issue:3

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Etoposide; Female; Half-Life; Humans; Irinotecan; Linear Models; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Reference Values; Remission Induction; Taxoids

2012
Paclitaxel inhibits ovarian tumor growth by inducing epithelial cancer cells to benign fibroblast-like cells.
    Cancer letters, 2012, Dec-30, Volume: 326, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Cell Differentiation; Cell Line, Tumor; Female; Fibroblasts; Humans; Immunohistochemistry; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel

2012
Doublet chemotherapy in the elderly patient with ovarian cancer.
    The oncologist, 2012, Volume: 17, Issue:11

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Clinical Trials as Topic; Female; Geriatric Assessment; Humans; Injections, Intraperitoneal; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel

2012
Establishment of paclitaxel-resistant cell line and the underlying mechanism on drug resistance.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2012, Volume: 22, Issue:9

    Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Microarray Analysis; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Signal Transduction

2012
The "Leuven" paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study.
    Gynecologic oncology, 2013, Volume: 128, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies

2013
[Effect of evidence-based medicine on the decision of chemotherapy for epithelial ovarian cancer].
    Zhonghua fu chan ke za zhi, 2012, Volume: 47, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Drug Administration Routes; Evidence-Based Medicine; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel

2012
The effect of age on first-line chemotherapy for epithelial ovarian cancer and primary peritoneal carcinoma.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2013, Volume: 25, Issue:1

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2013
Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo.
    Oncology reports, 2013, Volume: 29, Issue:2

    Topics: Analysis of Variance; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Ovarian Epithelial; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Synergism; Female; Humans; Inhibitor of Apoptosis Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Necrosis; Neoplasms, Glandular and Epithelial; Oligopeptides; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Skin; Survivin; TNF-Related Apoptosis-Inducing Ligand; X-Linked Inhibitor of Apoptosis Protein

2013
A case of occult bowel perforation after a cycle of chemotherapy for advanced epithelial ovarian carcinoma.
    European journal of gynaecological oncology, 2012, Volume: 33, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Female; Humans; Intestinal Perforation; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel

2012
Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer.
    PloS one, 2012, Volume: 7, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Blood Proteins; Carcinoma, Ovarian Epithelial; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Regulatory Networks; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Principal Component Analysis; ROC Curve; Taxoids; Transcriptome

2012
Epigenetic silencing of BLU through interfering apoptosis results in chemoresistance and poor prognosis of ovarian serous carcinoma patients.
    Endocrine-related cancer, 2013, Volume: 20, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Cytoskeletal Proteins; Drug Resistance, Neoplasm; Epigenomics; Female; Gene Silencing; Humans; Methylation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; RNA, Small Interfering; Tumor Suppressor Proteins

2013
Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.
    Oncogene, 2014, Jan-30, Volume: 33, Issue:5

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Aurora Kinase A; Azepines; Carcinoma, Ovarian Epithelial; Cell Adhesion; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Female; Humans; Mice; Mitosis; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; RNA Interference; RNA, Small Interfering; src-Family Kinases; Xenograft Model Antitumor Assays

2014
Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer.
    Cancer medicine, 2012, Volume: 1, Issue:2

    Topics: Adult; Aged; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Middle Aged; Neoplasms, Glandular and Epithelial; Nuclear Proteins; Ovarian Neoplasms; Paclitaxel; RNA Interference; RNA, Small Interfering; Treatment Failure; Xenograft Model Antitumor Assays

2012
Dose-dense paclitaxel with carboplatin for advanced ovarian cancer: a feasible treatment alternative.
    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2013, Volume: 35, Issue:1

    Topics: Alberta; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Recombinant Proteins; Survival Rate

2013
Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013, Volume: 23, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; RNA, Small Interfering; Survivin; Young Adult

2013
Extraorbital sebaceous carcinoma with rapidly developing visceral metastases.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2003, Volume: 29, Issue:9

    Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Fatal Outcome; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Orbit; Paclitaxel; Sebaceous Gland Neoplasms; Taxoids; Viscera

2003
Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study.
    British journal of cancer, 2003, Sep-15, Volume: 89, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Docetaxel; Female; Humans; Middle Aged; Mixed Tumor, Mullerian; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Practice Guidelines as Topic; Prospective Studies; Radiotherapy Dosage; Survival Rate; Taxoids

2003
[A retrospective study of advanced ovarian cancer in our ward].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate

2003
Topotecan versus paclitaxel in second-line therapy: a lost opportunity for quality-of-life evaluation?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:9

    Topics: Antineoplastic Agents; Female; Follow-Up Studies; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Time Factors; Topotecan; Treatment Outcome

2004
Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-01, Volume: 23, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Time Factors

2005
Significance of the O6-methylguanine-DNA methyltransferase and glutathione S-transferase activity in the sera of patients with malignant and benign ovarian tumors.
    European journal of obstetrics, gynecology, and reproductive biology, 2005, Mar-01, Volume: 119, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cisplatin; Female; Glutathione Transferase; Gynecologic Surgical Procedures; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; O(6)-Methylguanine-DNA Methyltransferase; Ovarian Neoplasms; Paclitaxel

2005
Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy.
    Cancer cell, 2005, Volume: 7, Issue:3

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Carrier Proteins; Cell Line; Drug Resistance, Neoplasm; Drug Therapy, Combination; Gene Expression Regulation; Genes, ras; Humans; MAP Kinase Signaling System; Membrane Proteins; Mice; Mice, Knockout; Neoplasms, Glandular and Epithelial; Paclitaxel; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins; Pyrazines; Tumor Suppressor Protein p53

2005
Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2005, Volume: 88, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cross-Sectional Studies; Fallopian Tube Neoplasms; Female; Genital Neoplasms, Female; Hematologic Diseases; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome

2005
Non-enrolment of ovarian cancer patients in clinical trials: reasons and background.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Female; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Neoplasms, Second Primary; Ovarian Neoplasms; Paclitaxel; Patient Participation; Patient Selection; Prospective Studies; Retrospective Studies; Topotecan

2005
Does paclitaxel (Taxol) given after (111)In-labeled monoclonal antibodies increase tumor-cumulated activity in epithelial cancers?
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Oct-01, Volume: 11, Issue:19 Pt 2

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Female; Heterocyclic Compounds, 1-Ring; Humans; Immunoglobulin G; Indium Radioisotopes; Male; Mammary Neoplasms, Experimental; Mice; Neoplasm Transplantation; Neoplasms, Glandular and Epithelial; Paclitaxel; Prostatic Neoplasms; Radioimmunotherapy; Time Factors

2005
Epithelial-myoepithelial carcinoma of the submandibular gland with symptomatic lung metastases treated with chemotherapy.
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2006, Volume: 263, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Fatal Outcome; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Myoepithelioma; Neoplasms, Glandular and Epithelial; Paclitaxel; Radiotherapy Dosage; Submandibular Gland Neoplasms

2006
Improved survival with single-agent paclitaxel consolidation/maintenance therapy in advanced ovarian carcinoma.
    Oncology, 2006, Volume: 71, Issue:1-2

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Survival Rate

2006
Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma.
    Journal of cancer research and clinical oncology, 2007, Volume: 133, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Doxorubicin; Female; Humans; Markov Chains; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Topotecan

2007
Developmental chemotherapy and management of recurrent ovarian cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, May-15, Volume: 21, Issue:10 Suppl

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drugs, Investigational; Enzyme Inhibitors; Etoposide; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Recurrence; Research Design; Taxoids; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome

2003
Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum.
    BMC cancer, 2007, Aug-09, Volume: 7

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Membrane Permeability; Cisplatin; Female; Gastrointestinal Tract; Humans; Intestinal Absorption; Lactulose; Mannitol; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Sucrose; Trastuzumab; Xylose

2007
ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Nov-20, Volume: 25, Issue:33

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; DNA-Binding Proteins; Endonucleases; Female; Genotype; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phenotype; RNA, Messenger

2007
Ovarian cancer.
    Medical Section proceedings : the ... annual Meeting of the Medical Section of the American Council of Life Insurance. American Council of Life Insurance. Medical Section. Meeting, 1994

    Topics: Female; Humans; Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Survival Rate; United States

1994
Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.
    The Journal of clinical investigation, 1997, Sep-01, Volume: 100, Issue:5

    Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Drug Resistance; Female; Gene Expression; Humans; Molecular Sequence Data; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Tubulin; Tumor Cells, Cultured

1997
A retrospective review of paclitaxel-associated gastrointestinal necrosis in patients with epithelial ovarian cancer.
    Gynecologic oncology, 1997, Volume: 67, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Digestive System; Female; Humans; Middle Aged; Necrosis; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel

1997
[A case of epithelial cancer of the alveoli which responded favorably to the additional administration of UFT for refractory cancer after administration of carboplatin and docetaxel].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:4

    Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Glandular and Epithelial; Paclitaxel; Pulmonary Alveoli; Taxoids; Tegafur; Uracil

2000
Biological basis for chemo-radiotherapy interactions.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Cell Transformation, Neoplastic; Cisplatin; Combined Modality Therapy; Deoxycytidine; DNA Adducts; DNA Repair; Docetaxel; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Paclitaxel; Radiotherapy; Taxoids

2002